



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA)
Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24
CIN No. L74899DL1978PLC009181

Date: September 07th, 2021

The Manager Listing Agreement The National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051.	The Manager Listing Agreement The BSE Limited Pherojbhoy Jeejeebhoy Tower Dalal Street, Mumbai - 400 001.
CM Quote: JAGSNPHARM	SCRIP Code: 507789
Subject: Intimation for Notice of 42nd Annual General Meeting to be held through Video Conferencing or Other Audio-Visual Means, Book Closure and Record Date for remote E- voting and Dividend Eligibility.	

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30, 34, 42 and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform the following:

1. The 42nd Annual General Meeting ('AGM') of the members of Jagsonpal Pharmaceuticals Limited will be held on Thursday, September 30, 2021 at 11:00 A.M. (IST) through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") in accordance with the circular dated May 5, 2020 read with circulars dated April 8, 2020, April 13, 2020 and January 13, 2021 issued by the Ministry of Corporate Affairs and circular dated May 12, 2020 read with circular dated January 15, 2021 issued by the Securities and Exchange Board of India. Copy of Annual Report for Financial Year 2020-21 is enclosed;
2. The Company has provided the facility to vote by electronic means (remote e-voting as well as e-voting at the AGM) on all the resolutions set out in the AGM Notice to the members, who are holding shares on the Cut-off date i.e. Thursday, September 23, 2021. The remote e-voting will commence at 09:00 AM. (IST) on Monday, September 27, 2021 and end at 05:00 PM (IST) on Wednesday, September 29, 2021; and;
3. Pursuant to Section 91 of the Companies Act, 2013, the Register of Members and Share Transfer Books of the Company shall remain closed from Friday, September 24, 2021 to Thursday, September 30, 2021 (both days inclusive) for the purpose of AGM of the Company for the financial year ended 31st March, 2021 and determining the eligibility for the payment of dividend @ 20% on fully paid-up equity Share of face value of Rs. 5/- each of the Company, subject to approval of shareholders in the ensuing AGM.



4. 23rd September, 2021 will be the Cut-Off/Record date for the purpose of e-Voting and eligibility for Dividend, if declared. Those shareholders holding shares either in dematerialized form or in physical form, as on the close of business hours on 23rd September, 2021 will be entitled to avail the facility of remote e-voting as well as voting at the AGM.

Request you to take the afore-mentioned information in record and oblige.

For **JAGSONPAL PHARMACEUTICALS LIMITED**




Nandita Singh
Company Secretary & Compliance Officer

BOARD OF DIRECTORS

R.P.S. Kochhar
Jasbir Kaur Kochhar
Bharat Sinh
Ishpal Singh Ghai
Ashok Kuamr Pati
Mammen Mathew

Chairman & Managing Director
Non-Executive Director
Independent Director
Independent Director
Independent Director
Independent Director

CHIEF FINANCIAL OFFICER

Sanjiv Kumar Dudeja

COMPANY SECRETARY

Nandita Singh

AUDITORS

H.L. Bansal & Co.
Chartered Accountants

BANKERS

Punjab & Sind Bank
Central Bank of India

REGISTERED OFFICE

T-210 J, Shahpur Jat
New Delhi - 110 049
Tel. : 011-46181100 & 46119900
Fax : 011-26498341
E-mail : nandita.singh@jagsonpal.com
Website : www.jagsonpal.com
CIN: L74899DL1978PLC009181

Works

20 K.M. Mathura Road, Post Office
Amar Nagar Faridabad, Haryana - 121 003

REGISTRAR & SHARE TRANSFER AGENTS

MCS Share Transfer Agent Limited
F-65, 1st Floor, Okhla Industrial Area
Phase - I, New Delhi – 110020
Phone : 011-46106148

CONTENTS	
Notice of 42nd Annual General Meeting	3
Directors' Report	13
Secretarial Auditors' Report	20
Report on Corporate Governance	26
Certificate of Non-Disqualification of Directors	33
Auditors' Report	34
Financial Statement	38

NOTICE

NOTICE is hereby given that the 42nd Annual General Meeting of the members of **JAGSONPAL PHARMACEUTICALS LIMITED** will be held on Thursday, the 30th day of September, 2021 at 11:00 A.M. through Video Conferencing and other Audio Visual means however, the meeting will be deemed to have been held at Registered Office of the Company to transact the following business:

ORDINARY BUSINESS

- To receive, consider and adopt the Financial Statements of the Company for the year ended March 31st, 2021 including the Audited Balance Sheet as at March 31, 2021 and the Statement of Profit & Loss for the year ended on that date and the Reports of the Directors and Auditors thereon.
- To declare a final Dividend @ 20% on fully paid-up equity Share on face value of Rs. 5/- each for the financial year ended March 31st, 2021;

SPECIAL BUSINESS

- To approve the remuneration of the Cost Auditors for the financial year ending March 31, 2022.

To Consider and if thought fit, to pass, with or without modification(s), the following resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to the provisions of Section 148 and all other applicable provisions of the Companies Act, 2013 and the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof, for the time being in force), M/s. R. Krishnan, Cost Accountants (Memb. No. 7799), appointed by the Board on the recommendation of the Audit Committee of the Company, to conduct the audit of the cost records of the Company for the financial year ending March 31, 2022, be paid the remuneration as set out in the Statement annexed to the Notice convening this Meeting;

RESOLVED FURTHER THAT the Board of Directors of the Company or the Company Secretary be and are hereby authorized jointly and severally to do all, deeds and things which are necessary for the aforesaid appointment and to send the necessary intimation in prescribed form to Registrar of Companies”.

By the Order of the Board
Nandita Singh
Company Secretary
A48520

Place: New Delhi
 Date: 30th Day of June, 2021

NOTES:-

- In view of the ongoing COVID-19 pandemic, the Ministry of Corporate Affairs (MCA) vide its General Circular No. 14/2020 dated April 8, 2020, General Circular No. 17/2020 dated April 13, 2020, General Circular No. 20/2020 dated May 5, 2020, General Circular No. 22/2020 dated June 15, 2020, General Circular No. 33/2020 dated September 28, 2020, General Circular No. 39/2020 dated December 31, 2020 and Circular No. 02/2021 dated January 13, 2021 (collectively “MCA Circulars”) and Securities and Exchange Board of India (“SEBI”) vide its circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020 and circular No. SEBI/HO/CFD/CMD2/CIR/P/2021/11 dated January 15, 2021 (collectively “SEBI Circulars”), have permitted companies to conduct AGM through VC or OAVM, subject to compliance of various conditions mentioned therein. In compliance with the aforesaid MCA Circulars and SEBI Circulars and the applicable provisions of Companies Act, 2013 and rules made thereunder, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the 42nd AGM of the Company is being convened and conducted through VC / OAVM. The registered office of the Company shall be deemed to be the venue for the AGM.
- Explanatory Statement setting out the material facts concerning each item of Special Businesses to be transacted at the Annual General Meeting pursuant to Section 102 of the Companies Act, 2013, is annexed hereto and forms part of the Notice.
- The detailed procedure in respect of Voting Procedure through VC/OAVM VOTING is given in the notice.
- Since this AGM is being held pursuant to the MCA Circulars and SEBI Circulars through VC / OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of proxies by the Members will not be available for the AGM and hence the Proxy Form, Attendance Slip and route map of the AGM are not annexed to this Notice.
- Attendance of the Members participating in the AGM through VC/OAVM facility shall be counted for the purpose of reckoning the quorum under Section 103 of the Act.
- Corporate members attending the meeting through their authorized representatives pursuant to Section 113 of Companies Act, 2013 (“the Act”) are requested to send to the Company, at least 48 hours prior to the start of e-voting, scanned copies of the following documents through email cs@jagsonpal.com
 - a certified copy of the Board resolution authorizing their representatives
 - Photograph of the Representative
- Pursuant to the provisions of Section 91 of the Companies Act, 2013, the Register of Members and Share Transfer Books of the Company will remain closed during the Book Closure period, i.e., from Friday, September 24, 2021 to Thursday, September 30, 2021 (both days

- inclusive) for the purpose of Annual General Meeting.
8. Members are requested to intimate change, if any, in their address (with PIN Code), E-mail ID, nominations, bank details, mandate instructions, National Electronic Clearing Service (“NECS”) mandates, etc. under the signature of the registered holder(s) to M/s MCS Share Transfer Agent Limited, Registrar and Transfer Agent (“RTA”) of the Company (email id admin@mcsregistrars.com); or the Company and their respective Depository Participants.
 9. Relevant documents referred to in the Annual Report including Notice of AGM and Explanatory Statement are available electronically for inspection without any fee by the members from the date of circulation of this Notice up to the date of AGM. Members seeking to inspect such documents can send an email to cs@jagsonpal.com.
 10. The members who have not yet registered their e-mail ids with the Company may contact on (e-mail cs@jagsonpal.com) for registering their e-mail ids on or before the cut-off date fixed for entitling the members to cast their vote i.e. 23rd Day of September, 2021. The Company shall send the Notice to such members whose e-mail ids get registered within the aforesaid time enabling them to participate in the meeting and cast their votes.
 11. In terms of the aforesaid Circulars, the businesses set out in the Notice will be transacted by the members only through remote e-voting or through the e-voting system provided during the meeting while participating through VC facility.
 12. Pursuant to Section 72 of the Companies Act, 2013 read with Rule 19(1) of Companies (Share Capital and Debentures) Rules, 2014, members of the Company may nominate a person in whom the shares held by him/ them shall vest in the event of his/ their unfortunate death. Accordingly, members holding shares in physical form, desirous of availing this facility may submit nomination in Form SH-13 to RTA of the Company. In respect of shares held in dematerialised form, the nomination form may be filed with the concerned Depository Participant.
 13. The Notice of AGM and Annual Report will be sent to those Members / beneficial owners whose name will appear in the Register of Members / list of Beneficial Owners received from the Depositories as on **Friday, August 20, 2021**.
 14. The Securities and Exchange Board of India (SEBI) has mandated the submission of Permanent Account Number (PAN) by every participant in the Securities Market. Members holding shares in electronic form are, therefore, requested to submit their PAN to the Depository Participants with whom they maintain their demat accounts. Members holding shares in physical form should submit their PAN to the Company/Registrar & Transfer Agents i.e. M/s MCS Share Transfer Agent Limited.
 15. As per SEBI directions securities of listed companies can be transferred only in dematerialised form with effect from April 1, 2019. Members, holding shares in physical forms, are advised to dematerialize their shares.
 16. Subject to the provisions of the Act, the final equity dividend as recommended by the Board of Directors, if declared at the AGM, will be paid on or after Monday, October 05, 2021 to those members whose names appear:
 - a) in the Register of members of the Company after giving effect to valid share transfers lodged with the Company on or before Thursday, September 23, 2021 and
 - b) as beneficial owners as at the end of business hours on Thursday, September 23, 2021 as per the list furnished by National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) in respect of shares held in dematerialized form.
 17. Members who hold shares in physical form in multiple folios in identical names or joint holding in the same order of names are requested to send the share certificates to the Registrar and Share Transfer Agents of the Company for consolidation into a single folio.

Non-Resident Indian Members are requested to inform to the Registrar and Share Transfer Agents of the Company, immediately of:

 - a) Change in their residential status on return to India for permanent settlement.
 - b) Particulars of their bank account maintained in India with complete name, branch, account type, account number and address of the bank with pin code number, if not furnished earlier.
 18. Members are hereby informed that pursuant to Sections 124 and 125 of the Act and Investor Education and Protection Fund (Accounting, Audit, Transfer and Refund) Rules, 2016, as may be amended from time to time (IEPF Rules), dividend which is remaining unpaid/ unclaimed by shareholders for a period of seven consecutive years shall be transferred to IEPF. IEPF Rules mandate the companies to transfer the shares of members whose dividends remain unpaid/ unclaimed for a period of seven consecutive years, to the dematerialization account of IEPF Authority. The details of unclaimed dividends and its due dates for transfer to IEPF are available on the website of the Company. Members who have not claimed their dividend(s) so far in respect of the unclaimed dividend(s) and which is due for transfer to IEPF, are requested to write to the Company’s R&T Agent, well in advance before the respective due dates. The Members whose dividend(s) and/or shares have been transferred to IEPF Authority can now claim their dividend(s) and/or shares from the IEPF Authority by following the ‘Procedure to claim Refund’ as detailed on the website of IEPF Authority www.iepf.gov.in/IEPF/refund.html. Unclaimed final equity dividend for the financial year 2013-14 is due for transfer to IEPF by November, 2021. Members are required to claim their uncashed dividend, if any, for the financial year 2013-14.
 19. Members are requested to note that, dividends if not

encashed for a consecutive period of 7 years from the date of transfer to Unpaid Dividend Account of the Company, are liable to be transferred to the Investor Education and Protection Fund ("IEPF"). The shares in respect of such unclaimed dividends are also liable to be transferred to the demat account of the IEPF Authority. In view of this, Members are requested to claim their dividends from the Company, within the stipulated timeline. The Members, whose unclaimed dividends/shares have been transferred to IEPF, may claim the same by making an online application to the IEPF Authority in web Form No. IEPF-5 available on www.iepf.gov.in. For details, please refer to corporate governance report which is a part of this Annual Report

20. Member's attention is particularly drawn to the "Corporate Governance" section in respect to unclaimed and unpaid dividend.
21. In accordance with the provisions of Section 108 and other applicable provisions, if any, of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and amendments thereto and applicable provisions of the SEBI Listing Regulations, the Company has engaged NSDL to provide the facility of voting through electronic means to the members to enable them to cast their votes electronically in respect of all the businesses to be transacted at the aforesaid Meeting.
22. The facility of e-voting through the same portal provided by NSDL will be available during the Meeting through VC also to those Members who do not cast their votes by remote e-voting prior to the Meeting. Members, who cast their votes by remote e-voting, may attend the Meeting through VC but will not be entitled to cast their votes once again.
23. Voting rights of the members (for voting through remote e-voting or e-voting system provide in the Meeting itself shall be in proportion to shares of the paid-up equity share capital of the Company as on the cut-off date i.e. 23RD September, 2021. A person, whose name is recorded in the Register of Members or in the Register of Beneficial owners (as at the end of the business hours) maintained by the depositories as on the cut-off date shall only be entitled to avail the facility of remote e-voting or e-voting system provide in the Meeting.
24. Pursuant to section 101 and section 136 of the Companies Act, 2013 read with relevant Rules made thereunder, Companies can serve Annual Reports and other communications through electronic mode to those members who have registered their e-mail address either with the Company or with the depository. Members of the company, who have registered their e-mail address, are entitled to receive such communication in physical form upon request.
25. Queries on the Annual Report and operations of the Company, if any, may please be sent to the email cs@jagsonpal.com at least ten days prior to the date of the AGM so that answers may be provided at the Meeting.

26. In case of joint holders attending the Meeting, only such joint holder who is higher in the order of names will be entitled to vote.

27. **Voting through electronic means:**

A. Instructions for Remote E-Voting prior to the AGM

- I. The remote e-Voting period commences at **09:00 A.M. (IST) on Monday, September 27, 2021** and ends at **05:00 P.M. (IST) on Wednesday, September 29, 2021**. During this period, members of the Company holding shares either in physical form or in dematerialized form, as on the Cut-off date **Thursday, September 23, 2021** ("Cutoff date"), may cast their vote by remote e-Voting. No remote e-Voting shall be allowed beyond the aforesaid date and time and remote e-Voting module shall be disabled by NSDL upon expiry of the aforesaid period. Once the vote on a resolution is cast by the member, the member shall not be allowed to change it subsequently.
- II. The Members who have cast their vote by remote e-voting prior to the AGM may also attend and participate in the AGM through VC/ OAVM means, but shall not be entitled to cast their e-vote again.
- III. The voting rights of Members shall be in proportion to their shares in the paid-up equity share capital of the Company as on the cut-off date should treat this Notice for information purpose only.
- IV. Any person, who acquire shares and become Member of the Company after the date of electronic dispatch of the Notice and holding shares as on the cut-off date i.e. **September 23, 2021**, may obtain the login ID and password by sending a request at evoting@nsdl.co.in. However, if they are already registered with NSDL for remote e-voting then they can use their existing User ID and password to cast the vote.

- V. **How do I vote electronically using NSDL e-Voting system?** The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:-

Step 1: Access to NSDL e-Voting system
Step 2: Cast your vote electronically and join virtual meeting on NSDL e-Voting system

Details on Step 1 are mentioned below:

1. **Login method for remote e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.**

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
<p>Individual Shareholders holding securities in demat mode with NSDL.</p>	<p>1. NSDL IDeAS facility If you are already registered for the NSDL IDeAS facility (a) Please visit the e-Services website of NSDL Viz. https://eservices.nsd.com either on a Personal Computer or on a mobile. (b) On the e-Services home page click on the “Beneficial Owner” icon under “Login” which is available under ‘IDeAS’ section. (c) A new screen will open. You will have to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. (d) Click on “Access to e-Voting” under e-Voting services and you will be able to see e-Voting page. (e) Click on company name or e-Voting service provider i.e. NSDL and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. If you are not registered for IDeAS e-Services The option to register is available at https://eservices.nsd.com Select “Register Online for IDeAS Portal” or click at https://eservices.nsd.com/SecureWeb/IdeasDirectReg.jsp</p> <p>2. E-voting website of NSDL (a) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsd.com/ either on a Personal Computer or on a mobile. (b) Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. (c) A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. (d) After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.</p>
<p>Individual Shareholders holding securities in demat mode with CDSL</p>	<p>1. Existing users who have opted for Easi / Easiest, they can login through their user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest are https://web.cdslindia.com/myeasi/home/login or www.cdslindia.com and click on New System Myeasi. 2. After successful login of Easi/Easiest the user will be also able to see the E Voting Menu. The Menu will have links of e-Voting service provider i.e. NSDL. Click on NSDL to cast your vote. 3. If the user is not registered for Easi/Easiest, option to register is available at https://web.cdslindia.com/myeasi/Registration/EasiRegistration 4. Alternatively, the user can directly access e-Voting page by providing demat Account Number and PAN No. from a link in www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the demat Account. After successful authentication, user will be provided links for the respective ESP i.e. NSDL where the e-Voting is in progress.</p>

Individual Shareholders (holding securities in demat mode) login through their depository participants	<p>1. You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility.</p> <p>2. Once logged on you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature.</p> <p>3. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.</p>
--	--

Important Note:- Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at above mentioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 1020 990 and 1800 22 44 30
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at 022- 23058738 or 022-23058542-43

2. Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/ Member’ section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.

Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.

4. Your User ID details are given below :

<p>Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical</p> <p>a) For Members who hold shares in demat account with NSDL.</p> <p>b) For Members who hold shares in demat account with CDSL.</p> <p>c) For Members holding shares in Physical Form.</p>	<p>Your User ID is: 8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.</p> <p>16 Digit Beneficiary ID For example if your Beneficiary ID is 12***** then your user ID is 12*****</p> <p>EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***</p>
---	---

5. Password details for shareholders other than Individual shareholders are given below: -
 - (a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
 - (b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the ‘initial password’ which was communicated to you. Once you retrieve your ‘initial password’, you need to enter the ‘initial password’ and the system will force you to change your password.
 - (c) How to retrieve your ‘initial password’?
 - (i) If your email ID is registered in your demat account or with the company, your ‘initial

password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The pdf file contains your 'User ID' and your 'initial password'

(ii) If your email ID is not registered, please follow steps mentioned below in **process for those shareholders whose email ids are not registered.**

6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:
 - (a) Click on "Forgot User Details/Password?" (If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsd.com.
 - (b) Physical User Reset Password? (If you are holding shares in physical mode) option available on www.evoting.nsd.com.
 - (c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.co.in mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
 - (d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
8. Now, you will have to click on "Login" button.
9. After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system

How to cast your vote electronically and join General Meeting on NSDL e-Voting system

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle and General Meeting is in active status.
2. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/OAVM" link placed under "Join General Meeting".
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.

5. Upon confirmation, the message "Vote cast successfully" will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

Process for procuring user ID and password for e-voting for those shareholders whose email ids are not registered with the depositories / Company

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to (Company email id).
2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to (Company email id). If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at step 1 (A) i.e. Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.
3. Alternatively, shareholder/members may send a request to evoting@nsdl.co.in for procuring user id and password for e-voting by providing above mentioned documents.
4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

B. Instructions for E-Voting during the AGM

- I. The procedure for e-voting during the AGM is same as the instructions mentioned above for remote e-voting.
- II. Only those Members, who will be present at the AGM through VC/ OAVM facility and have not cast their vote on the resolutions through remote e-voting and are otherwise not barred from doing so, shall be eligible to vote through e-voting system during the AGM.

C. Instructions for attending the AGM through VC / OAVM

- I. Member will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for Access to NSDL e-Voting system. After successful login, you can see link of "VC/OAVM link" placed under "Join General meeting" menu against

company name. You are requested to click on VC/OAVM link placed under Join General Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.

II. The Members will be allowed to join the AGM through VC/OAVM facility, fifteen (15) minutes before the scheduled time of commencement of the AGM and shall be kept open throughout the proceedings of the AGM. The facility of participation at the AGM through VC/OAVM will be made available to atleast 1,000 members on first come-first-served basis. The large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors, etc. can attend the AGM without any restriction on account of first-come-first-served basis.

III. For ease of conduct, the Company is pleased to provide two way video conferencing facility to the Members who would like to express their views/ ask questions at the AGM. The Members may register themselves atleast seven (7) days in advance as a speaker by sending their request along with questions from their registered email address mentioning their name, DP ID and Client ID/ folio number, PAN, mobile number at cs@jagsonpal.com. Those members who have registered themselves as a speaker will only be allowed to express their views/ ask questions at the AGM. The Company reserves the right to restrict the number of speakers depending on the availability of time for the AGM. Members who do not wish to speak during the AGM but have queries regarding financial statements or other matters may send their queries seven (7) days before the AGM mentioning their name, DP ID and Client ID/ folio number, PAN, mobile number at cs@jagsonpal.com. These queries will be replied by the Company suitably by email.

IV. Members who need assistance before or during the AGM, can contact MCS Share Transfer Agent Limited on admin@mcsregistrars.com.

1. General Guidelines for shareholders:

1. Institutional/Corporate members (i.e. other than individuals, HUF, NRI, etc.) are required to send a scanned copy (PDF/JPG Format) of its Board Resolution/ Authorisation Letter, etc. authorizing its representative to attend the AGM through VC/OAVM on its behalf and to vote through e-voting. The said resolution/ authorization shall be sent to the Scrutinizer by email to contact@jagsonpal.bansal@gmail.com with a copy marked to evoting@nsdl.co.in.
2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key

in the correct password. In such an event, you will need to go through the "Forgot User Details / Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.

3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on toll free no.: 1800-1020-990/1800-224-430 or send a request at evoting@nsdl.co.in.
4. In case of any queries or grievances relating to e-Voting, you may contact Ms. Pallavi Mhatre - Manager, National Securities Limited "NSDL" "A" Wing, Trade Word, Kamala Mills Compound, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013, at Toll free Nos.: 1800 1020 990 & 1800 2244 30 or email at pallavid@nsdl.co.in. You may also contact or write to MCS Share Transfer Agent Limited, Amarjit - Senior Manager, F-65, Okhla Industrial Area, Phase - 1, New Delhi - 110020 on 011-41406148 and admin@mcsregistrar.com for any query relating to e-voting.

2. Other Instructions:

1. The Board of Directors has appointed Mr. Hiralal Bansal, Chartered Accountant, (Membership No. 086990), Partner of M/s. H.L. Bansal & Co. Chartered Accountants, has been appointed as 'Scrutinizer' to scrutinize the process of e-voting during the AGM and remote e-voting held before the AGM in a fair and transparent manner.
2. The Scrutinizer shall after the conclusion of e-voting at the AGM, unblock the votes cast through remote e-voting and e-vote cast during the AGM and shall make, not later than 3 days of the conclusion of the AGM, a consolidated Scrutinizer's Report of the total e-votes cast in favour or against, if any, to the Chairman or a person authorised by him in writing, who shall countersign the Scrutinizer's Report and declare the result of the voting forthwith.
3. The results of voting will be declared from the conclusion of the AGM i.e. on or before October 03, 2021 and the result declared along with the report of the Scrutinizer shall be placed on the website of the Company and on the website of NSDL immediately after declaration of result by the Chairman or a person authorised by him and the result shall also be communicated to the Stock Exchange.
4. Subject to receipt of requisite number of votes, the resolutions shall be deemed to be passed at the AGM scheduled to be held on Thursday, September 30, 2021.

COMMUNICATION ON TAX DEDUCTION AT SOURCE (TDS) ON DIVIDEND DISTRIBUTION

As you may be aware w.e.f. 1st April 2020, Dividend Distribution Tax u/s 115-O of the Income-tax Act, 1961 (“the IT Act”) payable by domestic companies on declaration of dividend has been abolished. Pursuant to this amendment, the Company would be under an obligation to deduct tax at source (“TDS”) in accordance with the provisions of the IT Act, from dividend distributed on or after 1st April 2020. Please take note of the below TDS provisions and information/document requirements for each shareholder:

Section 1: For all Members - Details that should be completed and /or updated, as applicable

- a. All Members are requested to ensure that the below details are completed and/or updated, as applicable, in their respective demat account/s maintained with the Depository Participant/s; or in case of shares held in physical form, with the Company, by 17th September 2021. Please note that these details as available on Record Date in the Register of Members/ Register of Beneficial Ownership will be relied upon by the Company, for the purpose of complying with the applicable TDS provisions:
 - i. Valid Permanent Account Number (PAN).
 - ii. Residential status as per the Act i.e. Resident or Non-Resident for FY 2021-22.
 - iii. Category of the Member:
 - 1. Mutual Fund
 - 2. Insurance Company
 - 3. Alternate Investment Fund (AIF) Category I and II
 - 4. AIF Category III
 - 5. Government (Central/State Government)
 - 6. Foreign Portfolio Investor (FPI) /Foreign Institutional Investor (FII): Foreign Company
 - 7. FPI/FII: Others (being Individual, Firm, Trust, AJP, etc.)
 - 8. Individual
 - 9. Hindu Undivided Family (HUF)
 - 10. Firm
 - 11. Limited Liability Partnership (LLP)
 - 12. Association of Persons (AOP), Body of individuals (BOI) or Artificial Juridical Person (AJP)

- 13. Trust
- 14. Domestic company
- 15. Foreign company.

- iv. Email Address.
- v. Address.

Section 2: TDS provisions and documents required, as applicable for relevant category of Members

Members are requested to take note of the TDS rates and document/s, if any, required to be submitted to the Company by 17th September 2021 for their respective category, in order to comply with the applicable TDS provisions.

I. For Resident Members:

- i. Mutual Funds: No TDS is required to be deducted as per section 196(iv) of the IT Act subject to specified conditions. Self-attested copy of valid SEBI registration certificate needs to be submitted
- ii. Insurance companies: No TDS is required to be deducted as per section 194 of the IT Act subject to specified conditions. Self- attested copy of valid IRDA registration certificate needs to be submitted.
- iii. Category I and II Alternative Investment Fund: No TDS is required to be deducted as per section 197A (1F) of the IT Act subject to specified conditions. Self-attested copy of valid SEBI registration certificate needs to be submitted.
- iv. Recognised Provident funds: No TDS is required to be deducted as per Circular No.18/2017 subject to specified conditions. Self- attested copy of a valid order from Commissioner under Rule 3 of Part A of Fourth Schedule to the IT Act, or Self-attested valid documentary evidence (e.g. relevant copy of registration, notification, order, etc.) in support of the provident fund being established under a scheme framed under the Employees’ Provident Funds Act, 1952 needs to be submitted.
- v. Approved Superannuation fund: No TDS is required to be deducted as per Circular No.18/2017 subject to specified conditions. Self-attested copy of valid approval granted by Commissioner under Rule 2 of Part B of Fourth Schedule to the IT Act needs to be submitted.
- vi. Approved Gratuity Fund: No TDS is required to be deducted as per Circular No.18/2017 subject to specified conditions. Self- attested copy of valid approval granted by Commissioner under Rule 2 of Part C of Fourth Schedule to the IT Act needs to be submitted.
- vii. National Pension Scheme: No TDS is required to be deducted as per Sec 197A (1E) of the IT Act.

viii. Government (Central/State): No TDS is required to be deducted as per Sec 196(i) of the IT Act.

ix. Any other entity entitled to exemption from TDS: Valid self-attested documentary evidence (e.g. relevant copy of registration, notification, order etc.) in support of the entity being entitled to exemption from TDS needs to be submitted.

x. Other resident Members:

1. TDS is required to be deducted at the rate of 10% u/s 194 of the IT Act.

2. No TDS is required to be deducted, if aggregate dividend distributed or likely to be distributed during the financial year to individual shareholder does not exceed ` 5000. Normal dividend/s declared in the preceding financial year 2020- 2021 would be considered as the basis to determine applicability of the said threshold for the entire financial year.

3. No TDS is required to be deducted on furnishing of valid Form 15G (for individuals, with no tax liability on total income and income not exceeding maximum amount which is not chargeable to tax) or Form 15H (for individual above the age of 60 years with no tax liability on total income).

4. TDS is required to be deducted at the rate of 20% u/s 206AA of the IT Act, if valid PAN of the shareholder is not available.

5. As per Finance Bill 2021, TDS is proposed to be deducted at twice the applicable rates, if Income Tax Return is not filed by the resident shareholders for preceding two financials years, for which the time limit for filing has expired. Post implementation clarity by CBDT and Finance Act 2021, if any additional documents are required by the Company, the Company will separately intimate such resident shareholders.

6. TDS is required to be deducted at the rate prescribed in the lower tax withholding certificate issued u/s 197 of the IT Act, if such valid certificate is provided.

II. For Non-resident Members:

i. **Any entity entitled to beneficial rate / exemption from TDS:** Valid self-attested documentary evidence (e.g. relevant copy of registration, notification, order, etc. by Indian tax authorities) in support of the entity being entitled to beneficial rate / exemption from TDS needs to be submitted. ii. Other non-resident Members:

a) TDS is required to be deducted at the rate of 20% (plus applicable surcharge and cess) u/s 196D of the IT Act (For FPI and FII) and u/s 195 of the IT

Act for other non-resident Members.

b) Shareholder may be entitled to avail lower TDS rate as per Agreement For Avoidance Of Double Taxation (DTAA) between India and the country of tax residence of the shareholder, on furnishing the below specified documents

1. Self-attested copy of PAN. In case PAN is not available, provide details as per Rule 37BC of the Income Tax Rules, 1962.

2. Self-attested copy of valid Tax Residency Certificate (TRC) obtained from the tax authorities of the country of which the shareholder is a resident;

3. Self-declaration in Form 10F; and

4. Self-declaration on letterhead of having no Permanent Establishment in India, Beneficial ownership of shares and eligibility to claim treaty benefits (as per Annexure 1 to this Communication).

c) TDS is required to be deducted at the rate prescribed in valid lower tax withholding certificate issued u/s 197 of the IT Act, if such valid certificate is provided.

Details and / or documents as mentioned above in Section 1 and Section 2, as applicable to the Member, need to be sent, duly completed and signed, through registered email address of the Member with PAN being mentioned in the subject of the email to reach cs@jagsonpal.com by 17th September, 2021. Please note that no communication in this regard, shall be accepted after 17th September, 2021.

Section 3: Other general information for the Members:

1. For all self-attested documents, Members must mention on the document "certified true copy of the original". For all documents being sent / accepted by email, the Member undertakes to send the original document/s on the request by the Company.

2. TDS will be deducted based on details of registered member only. Once TDS is deducted in the name of Registered Members/ Beneficial Owners as appearing on Record Date, no transfer of such TDS in the name of another person shall be entertained under any circumstances.

3. TDS deduction certificate will be sent to the Members' registered email address in due course.

4. Surcharge rates applicable for financial year 2021 - 22 for non-residents:

I. Individual, HUF, AOP, BOI, AJP, Trust

Dividend Income	Rate
Upto INR 50 lakh	Nil
Income exceeds INR 50 lakh but does not exceed INR 1 crore	10%
Income exceeds INR 1 crore	15%

II. Co-operative society or Firm, registered under applicable Indian law

Aggregate Income	Rate
Income exceeds INR 1 crore	12%

III. Foreign company

Aggregate Income	Rate
Income exceeds INR 1 crore but does not exceed INR 10 crore	2
Income exceeds INR 10 crore	5%

5. Normal dividend/s declared in the preceding financial year 2020 – 2021 would be considered as the basis to determine applicability of the surcharge rate.
6. Health and Education Cess of 4% is applicable for non-residents.
7. Equity shares of the Company, which were transferred by the Company in the name of Investor Education and Protection Fund ('IEPF') in terms of Section 124(6) of the Companies Act, 2013 and Rules framed thereunder, the TDS shall be deducted basis the available details of the underlying Members
8. Application of TDS rate is subject to necessary due diligence and verification by the Company of the shareholder details as available in Register of Members on the Book Closure Date, documents, information available in public domain, etc. In case of ambiguous, incomplete or conflicting information, or the valid information/documents not being provided, the Company will arrange to deduct tax at the maximum applicable rate.
9. In case TDS is deducted at a higher rate, an option is still available with the shareholder to file the return of income and claim an appropriate refund, if eligible. Once deducted, no claim shall lie against the Company in relation to TDS.
10. In the event of any income tax demand (including interest, penalty, etc.) arising from any misrepresentation, inaccuracy or omission of information provided / to be provided by the Member/s, such Member/s will be responsible to indemnify the Company and also, provide the Company with all information / documents and co-operation in any appellate proceedings.

Note: Above communication on TDS sets out the provisions of law in a summary manner only, as on the date of the communication, and does not purport to be a complete analysis or listing of all potential tax consequences. Shareholders should consult with their own tax advisors for the tax provisions applicable to their particular circumstances.

Explanatory Statement pursuant to section 102 of the Companies Act.

Pursuant to Section 102(1) of the Act, the following Explanatory Statement sets out material facts relating to the business under item no.3 of the accompanying Notice dated 30th June, 2021 convening the 42nd Annual General Meeting of the Company scheduled to be held on 30th September, 2021.

ITEM NO. 3

The Board of Directors of the Company has appointed M/s. R. Krishnan Cost Accountants as Cost Auditors of the Company to audit the accounts relating to drug formulations for the financial year ending March 31st, 2022. Remuneration of Rs. 1.75 lakh shall be payable to M/s. R. Krishnan Cost Auditors of the Company for the financial year ended 31 March, 2022, which was recommended by the Audit Committee to the Board of Directors and subsequently, was considered and approved by the Board of Directors.

In accordance with the provisions of Section 148 of the Act read with the Companies (Audit and Auditors) Rules, 2014, the remuneration payable to the Cost Auditor has to be ratified by the shareholders of the Company

None of the Directors or KMP of the Company or their relatives is concerned or interested financially or otherwise, in this resolution.

Directors' Report**To the members of Jagsonpal Pharmaceuticals Limited**

On behalf of the Board of Directors (the "Board") of the Company, it gives me immense pleasure to present the 42nd Board's Report, along with the Balance Sheet, Profit and Loss account and Cash Flow statements, for the financial year ended March 31, 2021.

1. Financial Performance

The standalone financial statements for the financial year ended March 31, 2021, forming part of this Annual Report, have been prepared in accordance with the Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs.

Key highlights of financial performance of your Company for the financial year 2020-21 are provided below:

(Rs. in Lakhs)

Particulars	Current Year	Previous Year
Revenue from Operations	18794.56	15856.78
Other Income	439.33	252.62
Operating Expenditure	16886.71	15003.53
Profit for the year before Interest, Depreciation & Amortization and Tax	2347.18	1105.87
Less:		
Financial Expenses	51.35	51.41
Depreciation	108.60	112.98
Profit before tax	2187.23	941.48
Exceptional Items	-	-
Provision for taxation	604.70	157.15
Deferred Tax	(123.30)	(2.75)
Profit after Tax	1705.83	787.08
Balance brought forward		4113.27
Profit available for appropriation		4900.35
Appropriations:		
Proposed Dividend	262	131
Additional Income Tax	0	0
Transfer to General Reserve	0	0
Balance carried forward	5858.87	4769.35

2. State of Company's Affairs

During the period ended 31st March, 2021, despite of the pandemic of COVID-19, the sales of the Company has been managed well and stood at Rs. 18794.56 lakhs as compared to the sales of previous year 31.03.2020 which was Rs. 15856.78 lakhs. The profit before tax barring exceptional items increased from Rs. 941.48 Lakhs to Rs. 2187.23 Lakhs during the year.

3. Dividend

Your directors are pleased to recommend a dividend at the rate of 20% per equity share of face value of Rs. 5/- each for the year ended 31st March, 2021. The Final Dividend, subject to the approval of Members at the Annual General Meeting on Thursday, 30th Day of September, 2021, will be paid on or after Monday, 5th Day of October, 2021, to the Members whose names appear in the Register of members of the Company after giving effect to valid share transfers lodged with the Company on or before Thursday, 23rd Day of September, 2021 and as beneficial owners as at the end of business hours on Thursday, 23rd Day of September, 2021 as per the list furnished by National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) in respect of shares held in dematerialized form.

The proposed dividend will absorb a sum of Rs. 261 Lakhs. In view of the changes made under the Income-tax Act, 1961, by the Finance Act, 2020, dividends paid or distributed by the Company shall be taxable in the hands of the Shareholders. Your Company shall, accordingly, make the payment of the Final Dividend after deduction of tax at source.

4. Transfer to Reserve

Directors did not propose to transfer any amount to the General Reserve.

5. Change in the Nature of Business, if any

During the year under review, there has been no change in the nature of business of the Company.

6. Material changes and commitments after the balance sheet date

There was no material change and commitment in the business operations of the Company affecting the financial position of the Company which have occurred between the end of the financial year of the Company to which the financial statements relate and the date of this report.

7. Details of Significant and Material Orders passed by the Regulators or Courts or Tribunals impacting the going concern status and company's operations in future

There was no significant and material order passed by the Regulators or Courts or Tribunals impacting the going concern status and Company's operations in future.

8. Details in respect of adequacy of Internal Financial Controls with reference to the financial statements

a The Company has appointed Internal Auditors to observe the Internal Control systems and effectiveness of its functioning who regularly monitor the workflow of the organization in terms of the approved policies of the Company. In every quarter Internal Auditors present the Internal Audit Report and Management comments on the Internal Audit observations;

- b) The Board of Directors of the Company has adopted various policies related to Related Party Transactions, Whistle Blower mechanism and other procedures for ensuring the orderly and efficient conduct of business. The Company's system of internal control has been designed to provide a reasonable assurance with regard to maintaining of proper accounting controls, monitoring of operations, safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information;
- c) The Company has ERP suite for a reliable, high end, comprehensive, disciplined and integrated business solution.

9. Deposits

During the year under review, the Company has not accepted any fixed deposit under Chapter V of the Companies Act, 2013 and as such, no amount on account of principal or interest on deposits from public was outstanding as on 31st March, 2021.

10. Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo

As stipulated under the provisions of Section 134(3) the Companies Act, 2013, read with the (disclosure of particulars in the report of Board of Directors) rules, Annexure 'A' contains the particulars pertaining to Conservation of Energy, Technology absorption and Foreign Exchange earnings and outgo.

11. Particulars of Employees

The Company continued to maintain cordial relations with its employees at all levels. No man-days were lost during the period due to industrial strike. The information as required under the Companies Act, 2013, read with the Companies (Particulars of Employees) Rules, is enclosed in "Annexure B" and forms part of this Report.

12. Auditors

a) Statutory Auditors:

As per the provisions of Section 139 of the Companies Act, 2013 M/s H.L. Bansal & Co., Chartered Accountants were appointed as the Statutory Auditors of the Company for the period of five years.

The Auditor's Report for the financial year 2020-21 does not contain any qualification, reservation or adverse remark. The Auditor's Report is enclosed with the financial statements in this Annual Report.

b) Secretarial Auditors:

Pursuant to provisions of Section 204 the Companies Act, 2013 and rules made there under, the Board has appointed. M/s Mukesh Arora & Co., Practicing Company Secretaries as Secretarial Auditors to conduct Secretarial Audit for the financial year 2021-22.

The Secretarial Auditors' Report for the year 2020-21 has been received from the Secretarial Auditors'. The report does not contain any qualification, reservation or adverse remark.

The report is annexed herewith as Annexure – "C".

During the year under review, the Company has complied with the applicable provisions of the Secretarial Standards.

c) Cost Auditors:

The Board has appointed M/s. R. Krishnan as Cost Auditor for the year 2021-22. The remuneration of the cost auditor is subject to the approval by the members.

The Company has made and maintained the cost records as specified by the Central Government under Section 148(1) of the Companies Act, 2013.

13. Share Capital

During the year under review, there is no change in the Share Capital of the Company.

14. Extract of the Annual Return

Pursuant to Section 92(3) and Section 134(3)(a) of the Companies Act, 2013, the Company has placed a copy of the Annual Return as at March 31, 2021 on its website at <https://www.apmindustries.co.in/wp-content/uploads/2021/08/Annual-Return-for-Financial-Year-2020-2021.pdf>. By virtue of amendment to Section 92(3) of the Companies Act, 2013, the Company is not required to provide extract of Annual Return (Form MGT-9) as part of the Board's Report.

15. Corporate Social Responsibility (CSR) Activities

The Board of Directors of the Company on the recommendation of CSR Committee has adopted a CSR Policy which inter-alia states the CSR activities to be undertaken by the Company. The Policy may be referred at the Company's official website. (Annexure)

16. Directors and Key Managerial Personnel:

a) Changes during the year under review:

During the year under review, there is no change in the Key Managerial Personnel.

b) Declaration by Independent Directors

The Company has received declarations / confirmations from all the Independent Directors of the Company as required under Section 149(7) of the Companies Act, 2013 read with Rule 6 of the Companies (Appointment and Qualification of Directors) Rules, 2014 and Regulation 25(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

c) Familiarization Program undertaken for Independent Directors

The Independent Directors are familiarized with the Company, their roles, rights, responsibilities in the Company, nature of the industry in which the Company operates, business model of the Company,

etc. pursuant to Regulation 25(7) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On appointment, the Independent Director is issued a Letter of Appointment setting out in detail, the terms of appointment, duties, responsibilities and expected time commitments. Each newly appointed Independent Director undergoes a formal induction program on the Company's operations, marketing, finance and other important aspects. The Company Secretary briefs the Director about their legal and regulatory responsibilities as a Director. The Directors are also explained in detail the various compliances required from them as a Director under the various provisions of the Companies Act, 2013, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, SEBI (Prohibition of Insider Trading) Regulations, 2015, the Code of Conduct of the Company and other relevant regulations.

d) **Key Managerial Personnel**

Mr. Rajpal Singh Kochhar, Chairman & Managing Director (CMD), Mr. Sanjiv Kumar Dubeja, Chief Financial Officer (CFO) and CS Nandita Singh, Company Secretary are the whole-time Key Managerial Personnel of the Company as per Section 203 of the Companies Act, 2013.

17. Annual evaluation of board's performance

Pursuant to the requirement of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, performance of each member of the Board/ Committees of Board is evaluated on an annual basis. The evaluation is done by the Board, the Nomination and Remuneration Committee and the Independent Directors with specific focus on the performance and effective functioning of the Board / Committees and individual Directors, the member under evaluation not being present in evaluation process.

The following were the Evaluation Criteria:

- a) For Independent Directors:
- Commitment to the fulfillment of directors' obligations and fiduciary responsibilities
 - Core Competencies, Knowledge and Skills
 - Professional Conduct
 - Duties, Role and Functions
 - Ability to contribute to and monitor good governance practices
 - Fulfillment of the Independence Criteria and their independence from the management
- b) For Executive Directors:
- Performance as Team Leader/Member
 - Evaluating Business Opportunity and analysis of Risk Reward Scenarios
 - Set Key Goals and Achievements
 - Professional Conduct and Integrity

- Flow of information to Board members and between the Board and management
- The quality and quantity of information

The Directors expressed their satisfaction with the evaluation process.

18. Number of Meetings of the Board of Directors

During the financial year ended 31st March, 2021, four Board Meetings were held on:

1. 29TH Day of July, 2020
2. 10TH Day of November, 2020
3. 12TH Day of February, 2021
4. 18TH Day of March, 2021

Details of the Board meetings held during the financial year have been furnished in the Corporate Governance Report forming part of this Annual Report.

19. Meetings of Independent Directors:

During the year under review, a meeting of Independent Directors was held on 12th February, 2021 wherein the performance of the Non-Independent Directors, the Chairman and the Board as a whole was reviewed. The Independent Directors at their meeting also assessed the quality, quantity and timeliness of flow of information between the Company's management and the Board of Directors of the Company.

20. Committees of the Board

The Company has constituted/re-constituted various Board level committees in accordance with the requirements of Companies Act 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Details of all the above Committees along with their composition and meetings held during the year under review are provided in the Report on Corporate Governance forming part of this Annual Report.

a) **Audit Committee**

The Audit Committee presently comprises of Capt. Bharat Singh, Chairman, Dr. Ishapl Singh Ghai, Dr. Ashok Kumar Pati, and Mrs. Jasbir Kaur Kochhar as Members. The powers, role and terms of reference of the Audit Committee covers the areas as contemplated under Regulation 18 and part C of Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Section 177 of the Companies Act, 2013 and such other functions as may be specifically delegated to the Committee by the Board from time to time. The terms of reference of the Audit Committee, particulars of meetings held and attendance thereat are mentioned in the Corporate Governance Report forming part of this Annual Report.

b) **Nomination And Remuneration Committee**

The Nomination and Remuneration Committee presently comprises of Capt. Bharat Singh, Chairman, Dr. Ishapl Singh Ghai, and Mrs. Jasbir Kaur Kochhar as Members. The powers, role and terms

of reference of the Nomination and Remuneration Committee covers the areas as contemplated under Regulation 19 and part D of Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Section 178 of the Companies Act, 2013, besides other terms as may be referred by the Board of Directors. The terms of reference of the Nomination and Remuneration Committee, particulars of meetings held and attendance thereat are mentioned in the Corporate Governance Report forming part of this Annual Report.

c) Stakeholders' Relationship/ Grievance Committee

The Stakeholders' Relationship/Grievance Committee presently comprises of Capt. Bharat Singh, Chairman, Dr. Ishapl Singh Ghai, and Mrs. Jasbir Kaur Kochhar as Members. The terms of reference of the Stakeholders' Relationship/Grievance Committee, particulars of meetings held and attendance thereat are mentioned in the Corporate Governance Report forming part of this Annual Report.

d) Corporate Social Responsibility Committee

The Corporate Social Responsibility Committee presently comprises of Capt. Bharat Singh, Chairman, Dr. Ishapl Singh Ghai, and Mrs. Jasbir Kaur Kochhar as Members. The terms of reference of the CSR Committee, particulars of meetings held and attendance there at are mentioned in the Corporate Governance Report forming part of this Annual Report.

21. Policy on Directors' Appointment and Remuneration

The Company has adopted a Nomination and Remuneration Policy on Directors' Appointment and Remuneration including criteria for determining qualifications, positive attributes, independence of a director and other matters as provided under Section 178(3) of the Companies Act, 2013. The Policy is enclosed as a part of this report in compliance with Section 134(3) of the Companies Act, 2013.

22. Whistle Blower Policy/Vigil Mechanism

The Company has established a vigil mechanism/ Whistle Blower Policy and oversees through the committee, the genuine concerns expressed by the employees and other Directors. The Company has also provided adequate safeguards against victimization of employees and Directors who express their concerns. The Company has also provided direct access to the chairman of the Audit Committee on reporting issues concerning the interests of co-employees and the Company. The Whistle Blower policy as approved by the Board has been uploaded on the website of the Company.

23. Disclosure as required under Section 22 of Sexual Harassment of Women at Workplace (Prevention, Prohibition And Redressal) Act, 2013

The Company as an organization is committed to provide a healthy environment to all its employees

and thus, does not tolerate any discrimination and/or harassment in any form. The Company has in place a Prevention of Sexual Harassment Policy in line with the requirement of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. The Company has set up Internal Complaint Committee which is chaired by a female employee of the Company. No complaints of sexual harassment were received during the financial year 2020-2021.

24. Subsidiaries, Associates and Joint Venture

The Company does not have any subsidiary/joint venture/associate companies within the meaning of Companies Act, 2013.

25. Particulars of Loan, Guarantee or Investments

Pursuant to Section 186 of the Companies Act, 2013 and Schedule V of the Listing Regulations, disclosure on particulars relating to Loans, Advances, Guarantees and Investments are provided as part of the financial statements.

26. Particulars of Contracts or Arrangements with Related Parties

All the transactions done with related parties for the year under review were on arm's length basis and are in compliance with the applicable provisions of the Act and SEBI (Listing Obligations & Disclosure Requirements), Regulation, 2015, There are no material significant related party transactions made by the Company with Promoters, Directors or Key Managerial Personnel etc. which may have potential conflict with the interest of the Company at large expect the transactions which are reported. Transactions with related parties entered by the Company in the normal course of business are periodically placed before the Audit Committee of the Company for its approval. The policy on materiality of Related Party Transactions and also on dealing with Related Party Transactions as approved by the Board of Directors is uploaded on the website of the Company.

27. Corporate Governance

Your Company is committed to achieve the highest standards of Corporate Governance and adheres to the Corporate Governance requirements set by the Regulators/ applicable laws. Our focus on corporate governance, where investor and public confidence in companies is no longer based strictly on financial performance or products and services but on a company's structure, its Board of Directors, its policies and guidelines, its culture and the behavior of not only its officers and directors, but also all of its employees.

Our approach is proactive, starting with our Leadership Team. It is also deeply ingrained in our corporate culture, guiding how we work and how we do business. We continually discuss by laws and governance practices, changing our policies when necessary and pointing out areas where we need to improve our performance. We also compare our practices to the criteria used by outside organizations to evaluate corporate performance.

A separate section on Corporate Governance standards followed by the Company, as stipulated under

regulation 34(3) read with schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed as an Annexure to this report. The report on Corporate Governance also contains certain disclosures required under the Companies Act, 2013.

A requisite certificate from M/s. H.L. Bansal & Co. Chartered Accountants, confirming compliance with the conditions of Corporate Governance as stipulated under the aforesaid schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is attached to the Corporate Governance Report.

28. Management Discussion and Analysis Report

A separate report on Management Discussion and Analysis relating to business and economic environment surrounding your company is enclosed as a part of the Annual Report.

29. Directors Responsibility Statement

Pursuant to Section 133 of the Companies Act, 2013 your Directors state that:

- a In the preparation of the Annual Accounts for the year ended March 31, 2021, the applicable accounting standards read with requirements set out under Schedule III to the Act, have been followed and there are no material departures from the same;
- b the Directors have selected such accounting policies and applied them consistently and have made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at March 31, 2021 and of the profit and loss of the Company for the year ended on that date;
- c the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- d the Directors have prepared the annual accounts on a going concern basis;
- e the Directors have laid down internal financial controls to be followed by the Company and that such systems are adequate and are operating effectively; and
- f the Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

30. Transfer to Investor Education and Protection Fund

Pursuant to the applicable provisions of the Companies Act, 2013, read with the IEPF Authority (Accounting Audit Transfer and Refund) Rules, 2016 ('the Rules') all unpaid or unclaimed dividends are required to be transferred by the Company to the IEPF established by the Central Government, after completion of seven years. Further, according to the rules, the shares in respect of which dividend has not been paid or claimed by the shareholders for seven consecutive years or more shall also be transferred to the demat account created by the IEPF Authority. Accordingly, the

Company has transferred the unclaimed and unpaid dividends. Further the corresponding shares will be transferred as per the requirement of the IEPF rules, details of which are provided on our website.

31. Compliance with Secretarial Standards on Board and General Meetings

During the year under review, your Company has complied with applicable Secretarial Standards issued by the Institute of Company Secretaries of India.

32. Listing with Stock Exchanges

Your Company is listed with BSE Ltd. and National Stock Exchange of India Ltd. and the Company has paid the Listing Fees to the said exchanges on time.

Cautionary Note

Certain statements in the 'Management Discussion and Analysis' section may be forward-looking and are stated as required by applicable laws and regulations. Many factors may affect the actual results, which would be different from what the Directors envisage in terms of the future performance and outlook. Investors are cautioned that this discussion contains forward looking statement that involve risks and uncertainties including, but not limited to, risks inherent in the Company's growth strategy, dependence on certain businesses, dependence on availability of qualified and trained manpower and other factors discussed. The discussion and analysis should be read in conjunction with the Company's financial statements and notes on accounts

Acknowledgement

The Board of Directors would like to record their appreciation and gratitude to all employees of the organisation for their active co-operation and involvement. Thanks are also due, to Jagsonpal customers, dealers, suppliers and bankers. The Directors also acknowledge with gratitude the valuable and timely advice, guidance and support received from Government authorities Securities and Exchange Board of India and Stock Exchanges in- functioning Company.

For and on behalf of the Board of Directors

RAJPAL SINGH KOCHHAR

Chairman & Managing Director
(DIN 00059492)

Place: New Delhi
Dated: 30/06/2021

MANAGEMENT DISCUSSION AND ANALYSIS

[Schedule V – Regulation 34(3) of SEBI (LODR) Regulations, 2015]

Introduction

Management Discussion and Analysis mainly comprise of the statements which, inter-alia, involve predictions based on perceptions and may, therefore, be prone to uncertainties. It is the sum total of the Company's expectations, beliefs, estimates and projections which are forward looking within the meaning of applicable laws and regulations. The actual results could differ materially from those expressed herein specifically or impliedly.

a) INDUSTRY STRUCTURE AND DEVELOPMENTS

The Indian chemical industry is an integral part of the Indian economy. It is a knowledge-based industry and touches lives in many ways. The Pharma Sector is a major contributor to the Indian economy in terms of foreign exchange earnings and employments.

The Indian pharma industry is set for growth, buoyed by both strong domestic consumption as well as export demand.

However, with positive sentiments for India, we expect to do well in coming years.

b) OPPORTUNITIES & THREATS

Over the past many years, governments across the world have given more importance to controlling healthcare costs to balance their overall budgets. The COVID-19 pandemic and the economic costs that it has extracted, may force governments to revisit this presumption and try to strike a balance between providing adequate healthcare and the ability to fund it. While the pandemic obviously highlighted the importance of having an optimum healthcare infrastructure, it has also ignited a fresh debate on globalisation versus localisation. There is also a gradual realisation that the COVID-19 virus is here to stay and that all of us will have to learn to coexist with the virus till an effective treatment or vaccine becomes available. The industry is trying to develop a potential vaccine at a frantic pace while simultaneously putting in efforts to test existing drugs which can potentially aid COVID-19 treatment.

c) SEGMENT-WISE PERFORMANCE

The Company has only one line of business, i.e., Pharmaceuticals during the year under review, hence no segment wise information is required. The Company has no activity outside India. Therefore, there is no geographical segment.

d) OUTLOOK

Reports suggest that the medicine use is expected to increase by over 24% from 2015 to 2020 to reach 4.5 trillion doses in 2020 and a value of USD 1.4 trillion. Increased usage by emerging countries and increase of volumes in developed markets is projected to be the reason for this.

We will continue to focus on growing each of our businesses faster than the market in which we operate. R&D investments in developing a differentiated generic pipeline as well as in building our specialty pipeline will continue in the coming years.

e) RISKS & CONCERNS

Company's business, financial condition and results of operations are subject to certain risks and liabilities that may affect the Company's performance and ability to achieve its objectives. The factors that the Company believes could cause its actual results to differ materially from expected and historical results have been discussed hereunder. However, there are other risks and uncertainties that may affect the Company's performance and ability to achieve its objectives that are not currently known to the Company, or which are deemed immaterial. The pandemic has also affected India, but the vaccination drive has picked up momentum Pan India and outlook remains positive.

f) INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY

The Company has a professional internal control system, which provides adequate safeguards and effective monitoring of transactions. The Company has a strong internal audit system and an Independent Internal Auditor. The Internal Auditor reports to the Chairman and the Audit Committee of the Board. Personnel of the Internal Auditor conduct periodical audits in all the areas to ensure that the Company's control mechanism is properly followed and all statutory requirements are duly complied with.

g) CAUTIONARY STATEMENT

Statements in the Management Discussion and Analysis describing the Company's expectations or predictions may be forward looking within the meaning of applicable laws or regulations. Actual results may differ materially from those expressed or implied.

For and on behalf of the Board

Rajpal Singh Kochhar
Managing Director
DIN: 0059492

Place: New Delhi
Date: June 30, 2021

Annexure 'A' To the Directors' Report**Conservation of Energy, Technology Absorption and Foreign Exchange Earnings / Outgo**

Particulars required by the section 134(3) (m) of the Companies Act, 2013 ("the Act") read with Rule 8(3) of the Companies (Accounts) Rules, 2014 and forming part of the Directors' Report for the financial year ended March 31, 2021.

A Conservation of Energy

Measures taken, additional investments and impact on reduction of energy consumption

Disclosure of particulars with respect to Conservation of Energy:

Power and Fuel Consumption

	2020-21	2019-20
Consumption - per unit of production	Not Applicable	Not applicable

Consumption

It is not feasible to maintain energy consumption data by product category because of the large number and variety of products with significantly different energy requirements.

B Technology Absorption

Disclosure of particulars with respect to Technology Absorption:

1. Efforts in brief made towards technology absorption, adaption and innovation

The Company continues to strive in developing technology and technical know-how for introduction of new products and formulation development. These are adapted, wherever necessary to local conditions.

2. Benefits derived as a result of the above efforts:

New product development, productivity and quality improvements, enhanced safety and environmental protection ensure a n d conservation of energy.

C Expenditure On R & D**(Rs. in Lakhs)**

Particulars	Mar 2021	Mar 2020
a) Capital Expenditure	8.90	22.34
b) Revenue Expenditure	34.58	15.41
TOTAL	43.48	37.75

1 The R & D Centre carries out Research and Development in the area of Bulk Drugs, Drugs Intermediates and Pharmaceuticals.

2 In-house R&D focus has resulted in considerably higher and cost-effective modifications in the packaging of several formulations, especially in the capsule & tablet sections.

D Foreign Exchange Earnings & Outgo**Rs. In Lakhs**

Particulars	Mar 2021	Mar 2020
Earnings	723.27	447.63
Outgo	517.12	37.84

For and on behalf of the Board of Directors
RAJPALSINGH KOCHHAR

Place: New Delhi
Dated: 30/06/2021

Chairman & Mg. Director
(DIN 00059492)

Annexure 'B' to the Director's Report

STATEMENT UNDER THE PROVISION OF SECTION 197 (12) OF THE COMPANIES ACT, 2013 READ WITH THE COMPANIES (APPOINTMENT & REMUNERATION OF MANAGERIAL PERSONNEL RULES, 2014).

Amt in Rs.

S. No.	Name of the Director/KMP	Designation	Qualification and Experience	Gross Remuneration	Net Remuneration
1.	Mr. Rajpal Singh Kochhar	Chariman & Managing Director	M.Sc (Pharmacy) USA (40 Years)	1,00,88,400.00	56,43,400

Gross Remuneration includes: Salary, Bonus, Commission, Allowance and Perquisites as per the Rules of the Company .

Net Remuneration excludes: 5 Contributions towards Recognized Provident Fund, Tax Deducted at Source-Value of Taxable perquisites

Annexure- C to the Director's Report

Form No. MR-3

Secretarial Audit Report

[Pursuant to section 204(1) of the Companies Act, 2013 and Rule No.9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

FOR THE FINANCIAL YEAR ENDED 31st March, 2021

To

The Members,

Jagsonpal Pharmaceuticals Limited

T-210 J, Shahpur Jat

New Delhi- 110049

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Jagsonpal Pharmaceuticals Limited (hereinafter called the Company). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts / statutory compliances and expressing opinion thereon.

Based on our verification of the Company's Books, Papers, Minute Books, Forms and Returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the audit period covering the financial year ended on 31ST March, 2021 ('Audit Period'), complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

1. We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31ST March, 2021 according to the provisions of:
 - (i) The Companies Act, 2013 (the Act) and the rules made thereunder;
 - (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
 - (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
 - (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of
 - (v) Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings (Not applicable to the company as there were no transactions under FEMA or Rules made thereunder during the financial year under review);
 - (vi) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act') viz.: -
 - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - (b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;

- (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009/2018 (not applicable as the company did not issue any security during the financial year under review.)
 - (d) The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999 (not applicable as the company has not granted any options to its employees during the financial year under review);
 - (e) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008 (not applicable as the company has not issued any debt securities during the financial year under review);
 - (f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
 - (g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 (not applicable on the company during the financial year under review.)
 - (h) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998/201/ (not applicable as the company has not bought back any of its securities during the financial year under review);
 - (vii) and other applicable laws like Factories Act, 1948, The Payment of Gratuity Act, 1972;
2. We have also examined compliance with the applicable clauses / regulations of the following:
 - (i) Secretarial Standards issued by The Institute of Company Secretaries of India i.e. Secretarial Standards-1 (Meeting of the Board of Directors) & Secretarial Standards-2
 - (ii) (General Meetings)
 - (iii) The Listing Agreements entered into by the Company Bombay Stock Exchange (BSE).
 - (iv) The Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015
 3. During the period under review, the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.
 4. We further report that:
 - (i) The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.
 - (ii) Adequate notice is given to all Directors to schedule the Board Meetings, agenda and detailed notes on

agenda were sent at least seven days in advance and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

(iii) All decision at Board Meeting and Committee are carried through while the dissenting members' views are captured and recorded as part of the minutes.

5. We further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

For Mukesh Arora & Co.
Practicing Company Secretaries
Mukesh Arora
Proprietor

Date: 29 June, 2021
Place: New Delhi

F.C.S No. 4819
C.P No. 4405

This report is to be read with our letter of even date which is annexed as Annexure-A and forms an integral part of this report

Annexure A of Fom No. MR-3

To
The Members,
Jagsonpal Pharmaceuticals Limited
T-210 J, Shahpur Jat
New Delhi- 110049

Our report of even date is to be read along with this letter.

1. Maintenance of Secretarial Records is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on audit.
2. We have followed the audit practices and process as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on the test basis to ensure that correct facts are reflected in Secretarial records. We believe that the process and practices we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and books of Accounts of the company.
4. Wherever required, we have obtained the management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provisions of corporate and other applicable laws, rules, regulations, standards is the responsibility of Management. Our examination was limited to the Verification of procedures on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For Mukesh Arora & Co.
Practicing Company Secretaries
Mukesh Arora
Proprietor

Date: 29 June, 2021
Place: New Delhi

F.C.S No. 4819
C.P No. 4405

ANNUAL REPORT ON CSR ACTIVITIES

1. A brief outline on CSR Policy of the Company

Corporate Social Responsibility ("CSR") at JPPL is the commitment of businesses to contribute to sustainable economic development by working with the employees, their families, the local community and the society at large to improve their lives in ways that are good for business and for its development.

In compliance with the provisions of Section 135 of the Companies Act, 2013 (the "Act") read with the Companies (Corporate Social Responsibility Policy) Rules, 2014, the Company has taken the following steps:

- Adoption of CSR Policy which has been placed on the Company's website www.jagsonpal.com
- While implementing CSR activities, the Company shall give priority to the area around its local limits.
- The Committee approved the following CSR activities which are in line with Schedule VII to the Act:
 - (a) Promoting Education
 - (b) Promotion of Health Care
 - (c) Promoting Charitable Dispensary

2. Composition of CSR Committee

The Composition of the Committee as on March 31, 2021 are as follows:-

S. No.	Name	Designation
1.	Mrs. Jasbir Kaur Kochhar	Member
2.	Capt. Bharat Singh	Chairman
3.	Dr. Ishpal Singh Ghai	Member

3. The web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the board are disclosed on the website of the Company

Composition of the CSR committee shared above and is available on the Company's website on <https://www.jagsonpal.com/investor-relations>

CSR Policy and Projects – <https://www.jagsonpal.com/investor-relations>

4. Details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014, if applicable:- Not Applicable

5. Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social Responsibility Policy) Rules, 2014 and amount required for set off for the financial year, if any:-

S. No.	Financial Year	Amount available for set-off from preceding financial years (Rs in Lakhs)	Amount required to be setoff for the financial year, if any (Rs in Lakhs)
	-	NIL	NIL

6. Average Net Profit of the Company as per Section 135 (5):- Rs. 118 Lakhs

7. (a) Two percent of average net profit of the Company as per section 135(5):- Rs. 2.36 Lakhs

(b) Surplus arising out of the CSR projects or programmes or activities of the previous financial years:- NIL

(c) Amount required to be set off for the financial year, if any:- NIL

(d) Total CSR obligation for the financial year (7a+7b- 7c): - Rs.2.36 Lakhs

8. (a) CSR amount spent or unspent for the financial year: -

Total Amount Spent for the Financial Year (Rs in Lakhs)	Amount Unspent (Rs in Lakhs)				
	Total Amount transferred to Unspent CSR Account as per section 135(6)		Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5)		
	Amount	Date of transfer	Name of the Fund	Amount	Date of transfer
2.36	NIL	-	-	NIL	-

(b) Details of CSR amount spent against ongoing projects for the financial year:-

S. No.	Name of the Project	Item from the list of activities in Schedule VII to the Act.	Local area (Yes/No)	Location of the project		Project duration	Amount allocated for the project (Rs in Lakhs)	Amount spent in the current financial Year (Rs in Lakhs)	Amount transferred to Unspent CSR Account for the project as per Section 135(6) (Rs in Lakhs)	Mode of Implementation - Direct (Yes/No)	Mode of Implementation Through Implementing Agency	
				State	District						Name	CSR Registration number
1	-	-	-	-	-	Nil	-	-	-	-	-	-

(c) Details of CSR amount spent against other than ongoing projects for the financial year:-

S. No.	Name of the Project	Item from the list of activities in Schedule VII to the Act	Local area (Yes/No)	Location of the project		Amount spent for the project (Rs. in Lakhs)	Mode of Implementation Direct (Yes/No)	Mode of Implementation - Through Implementing Agency	
				State	District			Name	CSR Registration number
1.	Covid – 19 Mitigation & Promotion of Healthcare services	(i)	Yes	Delhi	New Delhi	2.36	No	-	-
Total						2.36			

(d) Amount spent in Administrative Overheads:- NIL

(e) Amount spent on Impact Assessment, if applicable:- NIL

(f) Total amount spent for the Financial Year (8b+8c+8d+8e):- Rs. 2.36 Lakhs

(g) Excess amount for set off, if any:- NIL

9. (a) Details of Unspent CSR amount for the preceding three financial years:-

S. No.	Preceding Financial Year	Amount transferred to Unspent CSR Account under Section 135 (6) (Rs. in Lakhs)	Amount spent in the reporting Financial Year	Amount transferred to any fund specified under Schedule VII as per Section 135(6), if any			Amount remaining to be spent in succeeding financial years (Rs. in Lakhs)
				Name of the Fund	Amount (Rs. in Lakhs)	Date of transfer	
1	-	Nil	-	-	Nil	-	-

(b) Details of CSR amount spent in the financial year for ongoing projects of the preceding financial year(s):-

S. No.	Project ID	Name of the Project	Financial Year in which the project was commenced	Project duration	Total amount allocated for the project (Rs. in Lakhs)	Amount spent on the project in the reporting Financial Year (Rs. in Lakhs)	Cumulative amount spent at the end of reporting Financial Year (Rs. in Lakhs)	Status of the project Completed / Ongoing
1.	-	-	-	-	Nil	-	-	-

10. In case of creation or acquisition of capital asset, furnish the details relating to the asset so created or acquired through CSR spent in the financial year (asset-wise details)

(a) Date of creation or acquisition of the capital asset(s):- None

(b) Amount of CSR spent for creation or acquisition of capital asset:- NIL

(c) Details of the entity or public authority or beneficiary under whose name such capital asset is registered, their address etc.:- Not Applicable

(d) Provide details of the capital asset(s) created or acquired (including complete address and location of the capital asset):- Not Applicable

11. Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per section 135(5):-
Not Applicable

For and on behalf of the Board

Bharat Singh

Ishpal Singh Ghai

Place: New Delhi

Chairman in CSR Committee

Member in CSR Committee

Date: June 30, 2021

DIN: 00347364

DIN: 06551659

CERTIFICATE OF CHIEF FINANCIAL OFFICER

To,
The Board of Directors,
Jagsonpal Pharmaceuticals Limited,

I, **Sanjiv Kumar Dudeja**, Chief Financial Officer of **Jagsonpal Pharmaceuticals Limited**, on the basis of the review of the financial statements and cash flow statement for the year ended 31st March 2021 and to the best of my knowledge and belief, hereby certify that:

These statements do not contain any materially untrue statements or omits any material fact or contain statements that might be misleading.

These statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.

There are, to the best of my knowledge and belief, no transactions entered into by the Company during the year ended 31st March 2021 which, are fraudulent, illegal or in violation of the Company's Code of Conduct.

I accept responsibility for establishing and maintaining internal controls for financial reporting and that I have evaluated the effectiveness of internal control systems of the company pertaining to financial reporting and we have disclosed to the Auditors' and the Audit Committee those deficiencies in the design or operations of such internal controls of which, I am aware and the steps taken and/ or proposed to be taken to rectify these deficiencies.

I have indicated to the Auditors and the Audit Committee:
There have been no significant changes in the internal control over financial reporting during this year.
There have been no significant changes in the accounting policies during the year.

To the best of our knowledge and belief, there is no instance of significant fraud of which I have become aware and the involvement therein, of management or an employee having significant role in the Company's internal control systems over financial reporting.

Place: New Delhi
Dated: 30 June, 2021

Sanjiv Kumar Dudeja
Chief Financial Officer

Auditors' Certificate Regarding compliance of Conditions of Corporate Governance.

To
The Members of Jagsonpal Pharmaceuticals Limited

We have examined the compliance of conditions of Corporate Governance by Jagsonpal Pharmaceuticals Limited for the year ended 31 March 2021, as stipulated in respective regulations 34 (3) and clause b to (i) of sub regulation (2) of Regulation 46 and para C, D and E of schedule V of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations 2015 (collectively referred to as "SEBI Listing Regulation 2015").

The compliance of conditions of Corporate Governance is the responsibility of the Company's Management. Our examination was carried out in accordance with the Guidance note on Certification of Corporate Governance, issued by the institute of Chartered Accountants of India was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the SEBI Listing Regulations, 2015.

We state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

For H L Bansal & Co.
Chartered Accountants
(Firm's Registration No. 008563N
HIRA LAL BANSAL
Partner
(Membership No. 086990)

Place: Delhi
Date: 30/06/2021

Annexure to the Directors' Report

Corporate Governance Report

Pursuant to Regulations 17 to 27 and clauses (b) to (i) of sub-regulations (2) of Regulation 46 and paragraphs C, D, and E of Schedule V of the SEBI (Listing Obligations & Disclosures Requirements) Regulations, 2015.

1. Company's Philosophy on Code of Governance:

The Company's philosophy on Corporate Governance is to conduct its business affairs in a professional and transparent manner while adhering to high ethical values and morals and always striving for optimizing Shareholder's value. The Company considers good corporate governance to be a prerequisite for meeting the objective of maximizing shareholder's wealth in a sustained manner.

2. Board of Directors

- The Board comprises of Executive and Non-Executive Directors. The present strength of the Board of Directors is six Directors. The Chairman and the Managing Director is a whole time director, the remaining five being Non-Executive Directors, out of which four are Independent Directors and have expertise in their respective fields.
- The attendance at Board Meetings and last Annual General Meeting of each of the Directors during the financial year of the Company is as under:

Name of Director	Category	Attendance		Membership of other Board (Excluding Alternate Directorship & Directorship in Pvt. Companies)	No. of Committees in which Member (excluding Pvt. Companies)
		Board Meetings	Last AGM		
Mr. Rajpal Singh Kochhar	Managing Director	4	Yes	1	-
Capt. Bharat Sinh	Independent Director	4	Yes	-	3
Dr. Ishpal Singh Ghai	Independent Director	4	Yes	-	3
Mrs. Jasbir Kaur Kochhar	Non-Executive Director	4	Yes	-	3
Mr. Ashok Kumar Pati	Independent Director	3	No	-	1
Mr. Mammen Mathew	Independent Director	2	No	-	0

- During the year three board meetings were held on following dates:

July 29, 2020 November 10, 2020 February 12, 2021 March 18, 2021

Details of director appointed / re-appointed

During the year under review, there is no change in the composition of the board of directors.

B) Information placed before the Board of Directors

The following information is regularly placed before the Board of Directors

- Minutes of the Committees
- Information on recruitment etc. of Senior officer just below the Board level
- Annual budgets/plans
- Capital budgets
- Quarterly results
- Material communications from Government bodies
- Fatal or serious accidents, dangerous occurrences and pollution problems, if any.
- Material financial obligations
- Significant labor problems, if any.
- Sale of assets, investments etc. which is not in the normal course of business.
- Material transactions
- Compliance with statutory requirements

Besides above, all major decisions are considered by the Board.

3. Ethics / Governance Policies Committee

The company we strive to conduct our business and relationship in a dignified, distinctive and reasonable manner. We adhere to ethical standard and some of these codes and policies are:

- Code of Conduct for Directors and Senior Management

- Code of Conduct for Prohibition insider Trading
- Code of Practices and Procedures for fair Disclosure of Unpublished Price Sensitive Information (UPSI)
- Policy for Determining Materiality of Events and Information
- Policy for Preservation of Documents
- Archival Policy
- Policy for Determining Material Subsidiaries
- Vigil Mechanism and Whistle Blower policy
- Treatment of Related Party Transaction
- Corporate Social Responsibility Policy
- Policy on Sexual Harassment
- Policy for Selection of Directors and their Independence
- Remuneration Policy for Directors KPP's Employees

4. Audit Committee, Appointment & Vigil Mechanisms

The terms of reference and modify the role of the Audit Committee cover under Section 177 of the Companies Act, 2013 include inter-alia reviewing with management the quarterly and annual financial statements, adequacy of internal control systems and frequency and scope of internal audit, overseeing of company's financial reporting process, discussions with internal and external auditors of the company on the audit undertaken, recommending the audit fee, reviewing the internal audit undertaken and its findings, to review the functions of the whistle blower mechanism

The Audit Committee has two Non-Executive Independent Directors and two Non Executive directors as members:

- Capt. Bharat Singh, Dr. Ishpal Singh Ghai, Mr. Ashok Kumar Pati and Mrs. Jasbir Kaur Kochhar. The Chairman of the Committee is Capt. Bharat Singh. The Company Secretary acts as Secretary of the committee. The Internal Auditor and/or Statutory Auditors are invitees to the meeting. The quorum for the Committee meeting is two Directors.

The Committee had met four times during the financial year in July, November, February and March months of 2020- 2021.

5. Chart setting out the skills/expertise/competence of the board of directors

The Company's Board comprises qualified members who bring in the required skills, competence and expertise that allow them to make effective contributions to the Board and its committees. The Board members are committed to ensure that the Company's Board is in compliance with the highest standards of corporate governance.

In the table below, the specific areas of focus or expertise of Individual Board members have been highlighted. However, the absence of a mark against a member's name does not necessarily mean the member does not possess the corresponding qualification or skill.

Directors	Area of Expertise					
	General Management and Business Operations	Leadership	Financials	Risk Management	Board service and Governance	Sales and Marketing
Shri Rajpal Singh Kochhar Chariman & Managing Director	✓	✓	✓	✓	✓	✓
Smt. Jasbir Kaur Kochhar Non-Executive Director	✓	✓	-	-	✓	-
Capt. Bharat Singh Independent Director	✓	✓	✓	✓	✓	-
Dr. Ishpal Singh Ghai Independent Director	✓	✓	✓	✓	✓	-
Dr. Ashok Kumar Pati Additional Independent Director	✓	✓	✓	✓	✓	✓
Mr. Mammen Mathew Additional Independent Director	✓	✓	✓	✓	✓	✓

6. Remuneration Committee and appointment, remuneration of Directors & Policy Nomination and Remuneration Committee

The Company has a policy to appoint Independent Director Personnel as director with requisite qualification & experience given below:

Name of the Member	Designation
Mr. Bharat Sinh	Chairman
Mrs. Jasbir Kaur Kochhar	Non Executive Woman Director
Dr. Ishpal Singh Ghai	Non Executive Independent Director

The Independent Directors of your Company have confirmed that (a) they meet the criteria of Independence as prescribed under Section 149 of the Act and Regulation 16 of the Listing Regulations, (b) they are not aware of any circumstance or situation, which could impair or impact their ability to discharge duties with an objective independent judgement and without any external influence (c) their name were included in the data bank of Independent Directors maintained by Indian Institute of Corporate Affairs under Rule 6 (3) of the Companies (Appointment and Qualification of Directors) Rules, 2014. Further, in the opinion of the Board, the Independent Directors fulfil the conditions prescribed under the Listing Regulations and are independent of the management of the Company.

The Company has complied with the provisions with respect to appointment and term of Independent Directors which are consistent with the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Independent Directors on the Board of the Company are given a formal appointment letter inter alia containing the terms of appointment, role, duties and responsibilities, code of conduct etc. The terms and conditions of appointment are available on the website of the Company at www.jagsonpal.com.

Brief Description of Terms of Reference

- To identify persons who are qualified to become Directors and who may be appointed in the senior management;
- To formulate a criteria for determining qualifications, positive attributes and independence of a director;
- To recommend to the Board, appointment and removal of the identified directors and senior management personnel based on the laid down criteria and formulated policy;
- To formulate criteria for evaluation of Independent Directors and the Board and shall carry out evaluation of every director’s performance;
- To review the performance of the Managing Director and Whole-time Director and recommend to the Board in this regard.
- To devise a policy on the Board diversity;
- To recommend to the Board a policy relating to the remuneration for the directors, key managerial personnel and other employees;
- To review the overall compensation policy and service agreements of the Managing Director and Whole-time Directors and other employees of appropriate cadres;
- To evaluate the remuneration paid by comparable organizations;

Listing Regulations mandates that the Board shall monitor and review the Board evaluation framework.

The evaluation of all the directors and the board as a whole was conducted based on the criteria and framework adopted by the Board. The evaluation process has been explained in the corporate governance report section in this Annual Report. The Board approved the evaluation results as collated by the nomination and remuneration committee.

Remuneration Policy

The Company’s inter-alia remuneration policy is determined by the success and performance of the individual employee of the company. The performance of the individual employee is measured through an annual appraisal process. The company, through its compensation program attracts, develops, motivates and retains its talented workforce. The managerial remuneration including perquisites thereof payable to Directors are determined by the Committee and shareholders. The remuneration of the directors during the period starting from 01st April, 2020 to 31st March, 2021 was as follow:

a. Managing Director/Whole Time Director:

Name	Remuneration
Shri Rajpal Singh Kochhar	Rs. 100.88 lacs

The above remuneration includes Salary, Bonus, Commission, Allowances and perquisites as per the rules of the Company.

b. Non-Executive Directors:

The Non-Executive Directors were paid remuneration by way of Sitting Fees Rs. 10,000/- for every Board Meeting and Rs. 2,500/- for committee meetings plus reimbursement of related actual travel and out of pocket expenses. They are entitled up

to 1% commission as and when approved by the Board of Directors. During the year remuneration paid to non-executive directors was as follows:

Name of Directors	Sitting Fee (Rs. In Lakhs)	Commission (Rs. Lakhs)
Mr. Bharat Sinh	Rs. 0.475	2
Mrs. Jasbir Kaur Kochhar	Nil	Nil
Dr. Ishpal Singh Ghai	Rs. 0.475	2
Mr. Ashok Kumar Pati	Rs. 0.375	Nil
Mr. Mammen Mathew	Rs. 0.2	Nil

7. Stakeholders' Relationship Committee

Pursuant to the Listing Regulations and Section 178 of the Act Stakeholders' Relationship Committee considers and resolves the grievances of security holders.

The complaints/queries/requests received from the shareholders have been duly attended to and resolved by furnishing requisite information/documents by the Company. A summary of complaints received and resolved by the Company during the financial year is given below:

The complaints received during the year under review are as follows:

Correspondence in the nature of complaints	Q1	Q2	Q3	Q4	Total
At the beginning of the quarter	0	0	0	0	0
Received during the quarter	0	0	0	0	0
Resolved during the quarter	0	0	0	05	0
Pending at the end of the quarter	0	0	0	0	0

8. Corporate Social Responsibility (CSR) Committee

The Corporate Social Responsibility Committee comprise of the following members:

Name of the Member	Designation
Mr. Bharat Sinh	Chairman
Mrs. Jasbir Kaur Kochhar	Non Executive Woman Director
Dr. Ishpal Singh Ghai	Non Executive Independent Director

The Company Secretary of the Company is the secretary to the Committee and the composition of the Committee meets the requirements of section 135 of the Act.

9. The Company's Code of Conduct for Prevention of Insider Trading

The Board of Directors has adopted the Trading Policy in accordance with the requirements of the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time. The Insider Trading Policy of the Company lays down guidelines and procedures to be followed, and disclosure to be made while dealing with shares of the Company, as well as the consequence of violation. The Policy has been formulated to regulate, monitor and ensure reporting of deals by employees and to maintain the highest ethical standards of dealing in Company Securities.

10. Listing Regulations

The Securities and Exchange Board of India (SEBI), on September 2, 2015, issued SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The said regulations were effective December 1, 2015. Accordingly, all listed entities were required to follow these regulations.

11. General Meetings

(a) Details of the last three years' General Meetings is given below:

Year ended	Date and time	Place	Resolutions passed
31.03.2018	28.09.2018 10.00 am	Vanita Samaj, 13, Institutional Area, Lodi Road, New Delhi 110003	O - 2 S - 5
31.03.2019	30.09.2019 10.00 am	Vanita Samaj, 13, Institutional Area, Lodi Road, New Delhi 110003	O - 2 S - 1
31.03.2020	30.09.2020 10.00 am	Registered Office	O-2 S-4

All the resolutions set out in the respective Notices were passed by the requisite majority of the members attending the AGM. All the resolutions set out in the notices were passed by the members.

12. Compliance Certification of The Auditors

Certification from the Company’s Auditors, M/s. H.L. Bansal & Co. confirming compliance with conditions of Corporate Governance as stipulated by SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is attached to this report.

13. Audit Certification

The Company is in the regime of unqualified financial statements.

14. Reporting of Internal Auditor

The Internal Auditor directly reports to the Audit Committee.

15. CEO Certification

The Chairman and Managing Director and the Chief financial Officer of the Company give annual certification on the financial reporting and internal control of the Board in terms of applicable clause and other applicable provisions SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

16. Disclosures

In terms of provisions of Investors Education & Protection Funds (IEPF) under Section 125, the dividends that remained unclaimed/ unpaid for a period of seven years from the date on which they were transferred to the respective unpaid dividend A/c have been transferred to IEPF, and in future the Company shall do the same as per directives of MCA, Government of India.

The details of such unpaid unclaimed dividend A/c as on 31.3.2021 are as under:

Dividend A/c Balance as on 31.03.2021

2012-2013	868970.00
2013-2014	419344.50
2014-2015	90769.00
2015-2016	128785.80
2016-2017	1137121.10
2017-2018	92949.20
2018-2019	168479.75
2019-2020	282186.50

17. Means of communications

As the quarterly results are published in one English daily newspaper (Business Standard) and one Hindi newspaper (Business Standard) published from Delhi. The quarterly/half yearly report was not sent to the shareholders.

During the financial year the Company has not made any presentations to the institutional investors or analysts. The Management Discussion and Analysis Report is part of this Annual Report.

18. General Shareholder Information

- Annual General Meeting : Thursday, 30th September, 2021.
Through Video Conferencing or Other Audio Visual Means
- Date of Book Closure : September 24th to September 30th, 2021 (both days inclusive)
- Dividend Payment Date : Within Stipulated Time, if declared.
- Financial Calendar (tentative)

Results for the quarter ending

June 2021	13 th August, 2021
September 2021	2 nd week of November, 2021
December 2021	2 nd week of February 2022
March 2022	4 th week of May 2022

High/Low of market price of the Company's shares traded along with the volumes on Bombay Stock Exchange, Mumbai and on the National Stock Exchange during the April 2020 to March 2021 is furnished below:

Period	BSE High (Rs.)	BSE Low (Rs.)	Volume No of Share	NSE High (Rs.)	NSE Low (Rs.)	Volume No of Share (In lakhs)
Apr-2020	32	16.55	368641	31.45	16.75	382.35
May-2020	28.85	22.45	50110	28.90	23.00	66.38
Jun-2020	45.2	24.05	395537	45.25	24.00	618.33
Jul-2020	49.4	33.55	227429	49.45	33.40	611.94
Aug-2020	45	31.5	691372	45.00	34.05	1,474.00
Sept-2020	43.35	33.5	204646	43.50	33.05	469.56
Oct-2020	46.5	37.5	248444	46.50	37.00	856.68
Nov-2020	76.1	37.6	1500856	76.05	37.35	5,726.34
Dec.-2020	78	57.3	1075408	78.50	56.60	3,778.85
Jan-2021	89.25	71	828031	89.05	71.00	4,106.49
Feb-2021	101.95	73	1477227	102	72.85	5,188.77
Mar-2021	97.35	75.9	4270195	97.50	75.65	6,592.18

- Listing on Stock Exchanges : The Bombay Stock Exchange Limited, Mumbai
The National Stock Exchange of India Limited, Mumbai
The Company has paid the listing fee for 2020-21.
- Scrip Code JAGSNPHARM at NSE and 507789 at BSE
- Stock Code : JAGSNPHARM EQ at NSE and 507789 at BSE
- ISIN No. for NSDL & CDSL : INE048B01027

Address for correspondence and Registrar and Transfer Agents

The company has appointed M/s. MCS Share Transfer Agent Limited as Registrar and Share Transfer Agents. For matters related to the shares following may be contacted.

Company Secretary Jagsonpal Pharmaceuticals Ltd. T-210 J, Shahpur Jat, New Delhi 110049.	MCS Share Transfer Agent Limited Unit: Jagsonpal Pharmaceuticals Ltd. F-65, Okhla Industrial Area, Ph. -I New Delhi 110020.
---	--

• SEBI Complaints redress systems (SCORES):

The investor complaints are processed in centralized web-based complaints redressal systems. The salient features of these systems are: Centralised database of all complaints, online upload of Action Taken reports (ATRs) by concerned companies and online viewing by investors of actions taken on the complaints and its current status.

• Designated Exclusive email-id exclusively for investors:

The Company has designated the following email-ids exclusively for investor servicing.

For Queries on in respect of shares in physical mode, Annual Reports, Dividend etc. cs@jagsonpal.com ; nandita.singh@jagsonpal.com ; sagar@jagsonpal.com

• Distribution of shareholding as on 31.03.2021

Range (Shares)	Number of Shareholders	Percentage of Shareholders	Number of Shares	Percentage of Shareholding
1-500	10179	81.133	1334829	5.096
501-1000	1427	11.375	1159464	4.425
1001-10000	881	7.22	2505232	9.563
10001-20000	31	0.247	413343	1.578
20001 & above	28	0.223	20785132	79.338

• **Dematerialisation of Securities**

Shares of the Company are actively traded on the Bombay Stock Exchange, Mumbai and the National Stock Exchange of India Limited. Approximately 98.86% of the Company's total shares have been dematerialized.

Action required regarding non-receipt of dividend

In case of non receipt of dividend warrants, members are to correspond with the Company's Registrar / Registrar of Companies as mentioned hereunder:

Dividend for	Contact Office	Action to take
2012-13 to 2020-21	MCS Share Transfer Agent Limited	Letter on plain paper
1991-92 to 2010-11	Balance remaining in the unpaid dividend accounts of respective years has been transferred to IEPF, Central Government	Balance remaining in the unpaid dividend accounts of respective years has been transferred to IEPF, (Central Government) Matter to be taken up with Ministry of Company Affairs Central Government
1986-87 to 1990-91	Not applicable due to non declaration of dividend	

- i) Pursuant to the provisions of the Companies Act 2013, all unclaimed dividends pertaining to the Company remaining unpaid or unclaimed for the period of 7 years from the date of became due for payment, have been transferred to the Investor Education Fund established by Central Government.

Plant Location

20 K. M. Mathura Road,
Post Office Amar Nagar Faridabad,
Haryana – 121 003

Address for Correspondence

The Company Secretary
Jagsonpal Pharmaceuticals Limited
T-210 J, Shahpur Jat, New Delhi – 110049
Phone : 011-46181100 & 46109900, Fax : 011 – 26498341, E-mail : cs@jagsonpal.com

Other facilities: Shareholders, who hold shares in a single name wish to make / change the nomination in respect of their shares as permitted under Section 109A of the Act, may submit to the registrar the prescribed Form 2B.

Bank details: Shareholders are requested to notify /send the following to the Company's registrar to facilitate better service.

- i. Any change in their address / mandate / bank details; and
- ii. Particulars of the bank account in which they wish their dividend to be credited, in case not furnished earlier.

Shareholders are advised that respective bank details and address as furnished by the Company will be printed on their dividend warrants as a measure of protection against fraudulent encashment.

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

(Pursuant to Regulation 34(3) and Schedule V Para C clause (10) (i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,
The Members of
Jagsonpal Pharmaceuticals Limited,
T-210 J, Shahpur Jat,
New Delhi, India-110049

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of **Jagsonpal Pharmaceuticals Limited** having CIN: **L74899DL1978PLC009181** and having registered office at T-210 J, Shahpur Jat, New Delhi, India- 110049 (hereinafter referred to as 'the Company'), produced before us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10 (i) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations/ representations furnished to us by the Company & its Director/officers, we hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on 31st March, 2021 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority:

Sr. No.	Name of Director	DIN	Date of appointment in Company
1	RAJPAL SINGH KOCHHAR	00059492	17/08/1978
2	BHARAT SINH	00347364	19/03/2013
3	JASBIR KAUR KOCHHAR	01460798	13/02/2015
4	ISHPAL SINGH GHAI	06551659	20/03/2013
5	MAMMEN MATHEW	00425579	14/11/2019
6	ASHOK KUMAR PATI	08661819	14/11/2019

Ensuring the eligibility of the appointment/ continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

Place: New Delhi
Date: 03.09.2021

For Mukesh Arora & Company
Practicing Company Secretaries
Sd/-
Mukesh Arora
M.NO-4819
COP-4405

INDEPENDENT AUDITORS' REPORT

TO THE MEMBERS OF JAGSONPAL PHARMACEUTICALS LIMITED

Report on the Indian Accounting Standards (Ind AS) Financial Statements

1. We have audited the accompanying Ind AS financial statements of Jagsonpal Pharmaceuticals Limited ("the Company"), which comprise the Balance Sheet as at March 31, 2021, the Statement of Profit and Loss (including Other Comprehensive Income), the Cash Flow Statement, Statement of changes in Equity and a summary of the significant accounting policies and other explanatory information.

Management's Responsibility for the Ind AS Financial Statements

2. The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Ind AS financial statements to give a true and fair view of the financial position, financial performance (including other comprehensive income), cash flows and changes in Equity of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards specified in the Companies (Indian Accounting Standards) Rules, 2015 (as amended) under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Ind AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

3. Our responsibility is to express an opinion on these Ind AS financial statements based on our audit.
4. We have taken into account the provisions of the Act and the Rules made there under including the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.
5. We conducted our audit of the Ind AS financial statements in accordance with the Standards on Auditing specified under Section 143(10) of the Act and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India. Those Standards and pronouncements require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Ind AS financial statements are free from material misstatement.
6. An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Ind

AS financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the Ind AS financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the Ind AS financial statements that give a true and fair view, in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the Ind AS financial statements.

7. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Ind AS financial statements.

Opinion

8. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Ind AS financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the Ind AS and other accounting principles generally accepted in India, of the state of affairs of the Company as at March, 31, 2021, and its total comprehensive income (comprising of Profit and other comprehensive income), its cash flows, the changes in Equity of the company and a summary of significant accounting policies and other explanatory information for the year ended on that date.

Report on Other Legal and Regulatory Requirements

9. As required by the Companies (Auditor's Report) Order, 2016, issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act ("the Order"), and on the basis of such checks of the books and records of the Company as we considered appropriate and according to the information and explanations given to us, we give in the Annexure B a statement on the matters specified in paragraphs 3 and 4 of the Order.
10. As required by Section 143 (3) of the Act, we report that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books,
 - (c) The Balance Sheet, the Statement of Profit and Loss (including other comprehensive income), the Cash Flow Statement and changes in Equity Report are in agreement with the books of account.
 - (d) In our opinion, the aforesaid Ind AS financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act.
 - (e) On the basis of the written representations received from the directors as on March 31, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.

- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in Annexure A.
- (g) With respect to the other matters to be included in the Auditors' Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our knowledge and belief and according to the information and explanations given to us:
- i. The Company has disclosed the impact, if any, of pending litigations as at March 31, 2021 on its financial position in its Ind AS financial statements - Refer Note 35
 - ii. The Company did not have any long-term contracts including derivative contracts as at March 31, 2021.
 - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company during the year ended March 31, 2021.

For H L Bansal & Co.
Chartered Accountants
(Firm's Registration No. 008563N)

HIRA LAL BANSAL
Partner

Place : Delhi

Date : 30/06/2021

(Membership No. 086990)
(UDIN: 21086990AAAADB5924)

ANNEXURE A TO INDEPENDENT AUDITORS' REPORT

Referred to in paragraph 10(f) of the Independent Auditors' report of even date to the Members of Jagsonpal Pharmaceuticals Limited on the Ind AS financial statements for the year ended March 31, 2021

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Act

1. We have audited the internal financial controls over financial reporting of Jagsonpal Pharmaceuticals Limited ("the Company") as of March 31, 2021 in conjunction with our audit of the Ind AS financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

2. The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the

prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors' Responsibility

3. Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing deemed to be prescribed under section 143(10) of the Act to the extent applicable to an audit of internal financial controls, both applicable to an audit of internal financial controls and both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.
4. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining and understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.
5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial reporting

6. A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

7. Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial control over financial reporting to future periods are subject to the risk that the internal financial controls over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

8. In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For H L Bansal & Co.
Chartered Accountants
(Firm's Registration No. 008563N)

HIRA LAL BANSAL
Partner

Place : Delhi

Date : 30/06/2021

(Membership No. 086990)
(UDIN: 21086990AAAADB5924)

ANNEXURE B TO INDEPENDENT AUDITORS' REPORT

Referred to in paragraph 9 of the Independent Auditors' report of even date to the Members of Jagsonpal Pharmaceuticals Limited on the Ind AS financial statements as of and for the year ended March 31, 2021

- i (a) The Company is maintaining proper records showing full particulars, including quantitative details and situation, of fixed assets.
- (b) The fixed assets are physically verified by the Management according to a phased programme designed to cover all the items over a period of three years which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the programme, a portion of the fixed assets has been physically verified by the Management during the year and no material discrepancies have been noticed on such verification.
- (c) The title deeds of immovable properties as disclosed in Note 3 on Property, Plant and Equipment to the Ind AS financial statements, are held in the name of the Company,
- ii. The Inventory except for goods in transit has been physically verified by the management at reasonable intervals during the year .In respect of inventory lying with

third parties, to the extent, such inventories have not been physically verified by the management, such inventories have been substantially confirmed by the third parties. The discrepancies noticed on physical verification of inventory as compared to book records were not material and have been appropriately dealt with in the books of accounts .

- iii. The Company has not granted any loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or other parties covered in the register maintained under Section 189 of the Act. Therefore, the provisions of Clause 3(iii), (iii)(a), (iii)(b) and (iii)(c) of the said Order are not applicable to the Company.
- iv. The Company has not granted any loans or provided any guarantees or security to the parties covered under section 185 of the Act. The company has complied with the provisions of section 186 of the Act in respect of investments made to the parties covered under section 186 of the Act.
- v. The Company has not accepted any deposits from the public within the meaning of Sections 73, 74, 75 and 76 of the Act and the Rules framed there under to the extent notified.
- vi. Pursuant to the rules made by the Central Government of India, the Company is required to maintain cost records as specified under Section 148(1) of the Act in respect of its products. We have broadly reviewed the same, and are of the opinion that, prima facie, the prescribed accounts and records have been made and maintained. We have not, however, made a detailed examination of the records with a view to determine whether they are accurate or complete.
- vii. (a) According to the information and explanations given to us and the records of the Company examined by us, in our opinion, the Company is generally regular in depositing the undisputed statutory dues, including provident fund, employees' state insurance, income tax, sales tax, service tax, customs duty, excise duty ,value added tax, Goods and Service Tax , cess and other material statutory dues, as applicable, with the appropriate authorities.

- (b) According to the information and explanations given to us and the records of the Company examined by us, the particulars of dues of income tax, sales tax, service tax, duty of customs and duty of excise value added tax as at March 31, 2021 which have not been deposited on account of a dispute, are as follows:

ANNEXURE OF CASE PENDING WITH VAT/SALES TAX AND OTHER LAWS

Nature of the statute	Nature of dues	Amount	Period to which the amount relates	Forum where the dispute is pending
Vat/Sale Tax Pune	Demand	1,79,53,179	2014 15	Sale Tax Authority
Vat/Sale Tax Pune	Demand	3,43,29,747	2015 16	Sale Tax Authority
Vat/Sale Tax Pune	Demand	9,36,720	2016-17	----do----
Vat/Sale Tax Kolkata	----do----	29,04,851	2008-2009	----do----
----do----	----do----	21,31,250	2008-2009 (CST)	----do----
----do----	----do----	16,70,707	2009-2010	----do----
Total		5,99,26,454		

viii. The Company has neither availed any loans or borrowings from any financial institution or bank or Government, nor has it issued any debentures as at the balance sheet date, the provisions of Clause 3(viii) of the Order are not applicable to the Company.

ix. The Company has not raised any moneys by way of initial public offer, further public offer (including debt instruments) and term loans. Accordingly, the provisions of Clause 3(ix) of the Order are not applicable to the Company.

x. During the course of our examination of the books and records of the Company, carried out in accordance with the generally accepted auditing practices in India, and according to the information and explanations given to us, we have neither come across any instance of material fraud by the Company or on the Company by its officers or employees, noticed or reported during the year, nor have we been informed of any such case by the Management.

xi. The Company has paid/provided for managerial remuneration in accordance with the requisite approvals mandated by the provisions of Section 197 read with Schedule V to the Act.

xii. As the Company is not a Nidhi Company and the Nidhi Rules, 2014 are not applicable to it, the provisions of Clause 3(xii) of the Order are not applicable to the Company.

xiii. The Company has entered into transactions with related parties in compliance with the provisions of Sections 177 and 188 of the Act. The details of such related party transactions have been disclosed in the Ind AS financial statements as required under Indian Accounting Standard (IndAS) Note 37, Related Party Disclosures specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

xiv. The Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review. Accordingly, the provisions of Clause 3(xiv) of the Order are not applicable to the Company.

xv. The Company has not entered into any non-cash transactions with its directors or persons connected with them. Accordingly, the provisions of Clause 3(xv) of the Order are not applicable to the Company.

xvi. The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, the provisions of Clause 3(xvi) of the Order are not applicable to the Company.

For H L Bansal & Co.
Chartered Accountants
(Firm's Registration No. 008563N)

HIRA LAL BANSAL
Partner
(Membership No. 086990)
(UDIN: 21086990AAAADB5924)

Place : Delhi
Date : 30/06/2021

Standalone Balance Sheet as at 31st March 2021			
(All amounts in Indian Rupees lacs, unless stated otherwise)			
	Notes	As at 31st March 2021	As at 31 March 2020
Assets			
Non-current assets			
Property, plant and equipment	3	2,334.66	2,206.02
Capital work-in-progress	3	-	190.34
Intangible assets	4	237.53	237.53
Financial assets			
(i) Investments	5A	1,205.84	1,138.68
(ii) Loans	6A	44.22	51.72
(iii) Other	7A	28.61	-
Non-current tax assets (net)	8	457.76	1,401.47
Deferred tax assets (net)	9	-	-
Other non-current assets	10A	63.91	12.96
		4,372.53	5,238.72
Current assets			
Inventories	11	2,972.45	2,932.50
Financial assets			
(i) Investments	5B	325.07	-
(ii) Loans	6B	26.77	32.89
(iii) Trade receivables	12	1,266.40	2,145.34
(iv) Cash and cash equivalents	13	5,894.29	3,981.30
(v) Bank balances other than (iv) above	14	128.69	67.21
(vi) Other	7B	25.03	36.09
Other current assets	10B	1,409.01	435.32
		12,047.71	9,630.65
Total assets		16,420.24	14,869.37
Equity and liabilities			
Equity			
Equity share capital	15	1,309.90	1,309.90
Other equity	16	10,883.01	9,793.49
Total equity		12,192.91	11,103.39
Non-current liabilities			
Financial liabilities			
(i) Borrowings	17A	-	-
(ii) Lease liabilities	18	-	-
Provisions	19	1.80	-
Deferred tax Lib(net)	9	185.86	309.16
		187.66	309.16

Current liabilities			
Financial liabilities			
(i) Borrowings	17B	678.79	640.37
(ii) Trade payables			
-total outstanding dues of micro enterprises and small enterprises		218.23	275.98
`-total outstanding dues of creditor other than micro enterprises and small enterprises	21	1,586.76	894.95
(iii) Lease liabilities	18	-	-
(iv) Other financial liabilities	22	438.25	390.71
Provisions	19	84.68	
Government grants	20	-	-
Current tax liabilities	23	382.15	829.98
Other current liabilities	24	650.81	424.83
		4,039.67	3,456.82
Total equity and liabilities		16,420.24	14,869.37
Summary of significant accounting policies	2		
The accompanying notes form an integral part of the financial statements			

As per our report of even date

For H L Bansal and CO.

Chartered Accountants

FRN. NO. 008563N

Hira Lal Bansal

Partner

M.No. 086990

Place: New Delhi

Date: 30 June 2021

For and on behalf of the Board of Directors

For Jagsonpal Pharmaceuticals Limited

R.P.S Kochhar

DIN 00059492

Chairman & Managing Director

S.K. Dudeja

Chief Financial Officer

Nandita Singh

Company Secretary

Standalone Statement of Profit and Loss for the Period ended 31st March 2021

(All amounts in Indian Rupees lacs, unless stated otherwise)

	Notes	For the year ended 31st March 2021	For the year ended 31 March 2020
Income			
Revenue from operations	25	18,794.56	15,856.78
Other income	26	439.33	252.62
Total income		19,233.89	16,109.40
Expenses			
Cost of raw and packing materials consumed	27	3,863.45	3,678.48
Purchase of traded goods		3,686.19	1,815.19
(Increase)/ decrease in inventories of finished goods, work-in-progress and traded goods	28	527.97	124.99
Employee benefits expense	29	5,398.12	5,037.42
Depreciation and amortisation expense	30	108.60	112.98
Finance costs	31	51.35	51.41
Other expenses	32	3,410.98	4,347.45
Total expenses		17,046.66	15,167.92
Profit before tax		2,187.23	941.48
Income tax expense	33		
Current Tax		604.70	157.15
Add: MAT credit written off of earlier years		-	-
Net current tax		604.70	157.15
Adjustment of tax relating to earlier periods		-	-
Deferred tax		(123.30)	(2.75)
Total tax expense		481.40	154.40
Profit for the year (A)		1,705.83	787.08
Other comprehensive income			
Items that will not be reclassified to profit or loss in subsequent periods:			
Re-measurement losses on defined benefit plans		21.39	-
Income tax effect	33	(6.23)	-

Other comprehensive income for the year, net of tax (B)		15.16	-
Total comprehensive income for the year (A+B)		1,720.99	787.08
Earnings per equity share	34		
Basic earnings per equity share (INR)		6.51	3.00
Diluted earnings per equity share (INR)		6.51	3.00

Summary of significant accounting policies

2

The accompanying notes form an integral part of the financial statements

As per our report of even date

For H L Bansal and CO.

Chartered Accountants

FRN. NO. 008563N

Hira Lal Bansal

Partner

M.No. 086990

Place: New Delhi

Date: 30 June 2021

For and on behalf of the Board of Directors

For Jagsonpal Pharmaceuticals Limited**R.P.S Kochhar**

DIN 00059492

Chairman & Managing Director

S.K. Dudeja

Chief Financial Officer

Nandita Singh

Company Secretary

Standalone Cash flow statement for the period ended 31st March 2021

(All amounts in Indian Rupees lacs, unless stated otherwise)

	For the year ended 31st March 2021	For the year ended 31 March 2020
A. Cash flow from operating activities		
Net Profit before tax	2,187.23	941.48
Other Comprehensive Income	15.16	
Depreciation and amortisation expense	108.60	112.98
Loss/ (profit) on sale of property, plant and equipment	-	(1.60)
Interest income	(299.24)	(216.80)
Interest expense	51.35	51.41
Prepaid Expense	12.96	-
Fair value gain on financial instruments at fair value through profit or loss	25.05	-
Deferred tax liability reduced	(123.30)	(2.75)
Operating profit before working capital changes	1,977.81	884.72
Movements in working capital:		
Decrease / (increase) in trade receivables	878.94	(70.32)
Decrease / (increase) in inventories	(39.95)	336.76
(Decrease / (increase) in other financial assets	(3.93)	(21.89)
Decrease / (increase) in other assets	(973.70)	6.59
(Decrease) / increase in trade payables	634.06	(15.11)
(Decrease) / increase in provisions	86.48	-
(Decrease) / increase in other financial liabilities	85.97	32.80
(Decrease / (increase) in tax assets	1,194.80	(21.47)
(Decrease) / increase in tax liabilities	(929.22)	(19.07)
(Decrease) / increase in other liabilities	225.98	255.52
Cash generated from operations	3,137.24	1,368.53
Income Tax paid	(315.00)	(180.00)
Net cash flow from operating activities (A)	2,822.24	1,188.53
B. Cash flow from investing activities		
Net of Sale/ Purchase of property, plant and equipment and intangible assets (including capital work-in-progress)	(46.91)	(185.47)
Purchase of investments	(417.28)	(1,138.63)
Interest received	237.76	216.80
Net cash (used in) / from investing activities (B)	(226.43)	(1,107.30)
C. Cash flow from financing activities		
Interest paid	(51.35)	(51.41)
Change in Equity	(369.47)	-
Dividend	(262.00)	(131.00)
Net cash from/ (used in) financing activities (C)	(682.82)	(182.41)

Net increase/(decrease) in cash and cash equivalents (A+ B+C)	1,912.99	(101.18)
Effect of exchange differences on cash and cash equivalents held in foreign currency	-	
Cash and cash equivalents at the beginning of the year	3,981.30	4,082.48
Cash and cash equivalents at the end of the year	5,894.29	3,981.30
Components of cash and cash equivalents		
Cash in hand	31.14	27.75
With banks	5,863.15	3,953.55
Total cash and cash equivalents (Note 13)	5,894.29	3,981.30

Summary of significant accounting policies

The accompanying notes form an integral part of the financial statements

As per our report of even date

For H L Bansal and CO.

Chartered Accountants

FRN. NO. 008563N

Hira Lal Bansal

Partner

M.No. 086990

Place: New Delhi

Date: 30 June 2021

For and on behalf of the Board of Directors

For Jagsonpal Pharmaceuticals Limited**R.P.S Kochhar**

DIN 00059492

Chairman & Managing Director

S.K. Dudeja

Chief Financial Officer

Nandita Singh

Company Secretary

Standalone Statement of Change in Equity for the year ended 31st March 2021

(All amounts in Indian Rupees lacs, unless stated otherwise)

(A) Equity share capital (Refer note 15):

Equity shares of INR 5 each issued, subscribed and fully paid	Amount
As at 1 April 2019	1,309.90
Buy back during the year	-
As at 31 March 2020	1,309.90
Buy back during the year	-
As at 31 March 2021	1,309.90

(B) Other equity (Refer note 16):

	General reserve	Securities premium account	Revaluation Reserve	Surplus/ (deficit) in the statement of profit and loss	Total other equity
As at 1 April 2020	4,180.22	60.00	783.92	4,769.35	9,793.49
Profit for the year	-	-	-	1,705.83	1,705.83
Other comprehensive income	-	-	-	15.16	15.16
Total comprehensive income for the year	-	-	-	1,720.99	1,720.99
Transactions with owners in their capacity as owners:					
Dividends paid	-	-	-	(262.00)	(262.00)
Tax on dividends paid	-	-	-	-	-
Earlier years adjustment in DBO and Income tax	-	-	-	(369.47)	(369.47)
As at 31 March 2021	4,180.22	60.00	783.92	5,858.87	10,883.01

	General reserve	Securities premium account	Revaluation Reserve	Surplus/ (deficit) in the statement of profit and loss	Total other equity
As at 1 April 2019	4,180.22	60.00	783.92	4,113.27	9,137.41
Profit for the year	-	-	-	787.08	787.08
Other comprehensive income	-	-	-	-	-
Total comprehensive income for the year	-	-	-	787.08	787.08
Transactions with owners in their capacity as owners:					
Dividends paid	-	-	-	(131.00)	(131.00)
Tax on dividends paid	-	-	-	-	-
As at 31 March 2020	4,180.22	60.00	783.92	4,769.35	9,793.49

The accompanying notes form an integral part of the financial statements

As per our report of even date

For H L Bansal and CO.
Chartered Accountants
FRN. NO. 008563N
Hira Lal Bansal
Partner

M.No. 086990
Place: New Delhi
Date: 30 June 2021

For and on behalf of the Board of Directors
For Jagsonpal Pharmaceuticals Limited

R.P.S Kochhar
DIN 00059492
Chairman & Managing Director

S.K. Dudeja
Chief Financial Officer

Nandita Singh
Company Secretary

Significant Accounting Policies**1. Company Overview**

Jagsonpal Pharmaceuticals Limited (“the Company”) is a domestic public company headquartered in Delhi, India. It is incorporated under the Companies Act, 1956 and its shares are listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and APIs. The Company has operations in India and caters to both domestic and international markets.

2. Significant Accounting Policies**A. Basis of Preparation of Financial Statements**

The financial statements comply in all material aspects with India Accounting Standards (Ind AS) notified u/s 133 of the Companies Act, 2013 (the Act) (Companies (Indian Accounting Standards) Rules, 2015, as amended) and other relevant provisions of the Act. The financial statements are prepared under the historical cost convention, except for certain fixed assets which are revalued, in accordance with the generally accepted accounting principles in India and the provisions of the Companies Act, 2013.

B. Use of Estimates

The preparation of financial statements requires estimates and assumptions to be made that affect the reported amount of assets and liabilities on the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Difference between the actual results and estimates are recognised in the period in which the results are known/ materialised.

C. Fixed Assets

The Company has elected to continue with the carrying value of all of its property, plant and equipment measured as per the previous GAPP (Indian GAPP) and use that carrying value as the deemed cost of the property, plant and equipment.

D. CAPITAL WORK IN PROGRESS

The Company has elected to continue with the carrying value of all of its capital work in progress measured as per the previous GAAP (Indian GAPP) and use that carrying value as the deemed cost of the capital work in progress for capitalisation purpose.

Intangible Assets are stated at cost of acquisition and development.

E. Depreciation and Amortisation

Depreciation on fixed assets is provided as per schedule II of the companies act, 2013. Land is not amortised.

F. Impairment of Assets

An asset is treated as impaired when the carrying cost of asset exceeds its recoverable value. An impairment loss is charged to the Profit and Loss Account in the year in which an asset is identified as impaired. The impairment loss recognised in prior accounting period is reversed if there has been a change in the estimate of recoverable amount. The company has elected to continue with the carrying value of all of its assets measured as per the previous GAPP (Indian GAPP) and use that carrying value as the deemed cost of the assets.

G. Foreign Currency Transactions

- (a) Transactions denominated in foreign currencies are recorded at the exchange rate prevailing on the date of the transaction or that approximates the actual rate at the date of the transaction.
- (b) Monetary items denominated in foreign currencies at the year end are restated at year end rates. In case of items which are covered by forward exchange contracts, the difference between the year end rate and rate on the date of the contract is recognised as exchange difference and the premium paid on forward contracts is recognised over the life of the contract.
- (c) Any income or expense on account of exchange difference either on settlement or on translation is recognised in the Profit and Loss account except in case of long term liabilities, where they relate to acquisition of fixed assets, in which case they are adjusted to the carrying cost of such assets.

H. Investments

Long Term Investments are stated at cost. Provision for diminution in the value of long-term investments is made only if such a decline is other than temporary. Short term investments are stated at fair market value.

I. Inventories

Items of inventories are measured at lower of cost and net realisable value after providing for obsolescence, if any. Cost of inventories comprises of cost of purchase, cost of conversion and other costs including manufacturing overheads incurred in bringing them to their respective present location and condition. Cost of raw materials, process chemicals, packing materials,

trading and other products are determined on weighted average basis.

J. Revenue Recognition

Revenue is recognized only when it can be reliably measured and it is reasonable to expect ultimate collection. Revenue from operations includes sale of goods adjusted for discounts (net), goods returned and breakages and expiry. Dividend income is recognized when received. Interest income is recognized on time proportion basis taking into account the amount outstanding and rate applicable.

K. Duties and taxes

Duties and taxes are accounted for in the books of accounts as per the prevailing law for the time being in force.

L. Employee Benefits :

The company participates in various employee benefit plans. Post employment benefits are classified as either defined contribution plans or defined benefits plans. Under a defined contribution plan, the Company's only obligation is to pay a fixed amount with no obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits. The related actuarial and investment risks fall on the employee. The expenditure for defined contribution plans is recognized as expense during the period when the employee provide service. Under a defined benefit plan, it is the Company's obligation to provide agreed benefits to the employees. The related actuarial and investment risks fall on the company. The present value of the defined benefit obligation is calculated using the projected unit credit method. The company has the following benefit plans :

- (i) Short-term employee benefits In the form of Contributions to Provident fund which are recognised as an expense at the undiscounted amount in the profit and loss account of the year in which the related service is rendered.
- (ii) Post employment and other long term employee benefits like Gratuity are recognised as an expense in the Profit and Loss account for the year in which the employee has rendered services. The expense is recognised at the present value of the amounts payable determined using actuarial valuation techniques. Actuarial gains and losses in respect of post employment and other long term benefits are charged to the Profit and Loss account as comprehensive income/loss. “

M. Borrowing Costs

Borrowing costs that are attributable to the acquisition or construction of qualifying assets are capitalised as part of the cost of such assets. A qualifying asset is one that necessarily takes substantial period of time to get ready for its intended use. All other borrowing costs are charged to Profit and Loss account.

N. Provision for Current and Deferred Tax

- a) Income Tax comprises current and deferred tax. Income tax expense is recognised in the statement of profit and loss except to the extent it related to items directly recognised in equity or in other comprehensive income. Provision for current tax is made after taking into consideration benefits admissible under the provisions of the Income-tax Act, 1961.
- b) Deferred income tax is recognised using the balance sheet approach from this year as compared to profit and loss approach in earlier. The impact of change in accounting policy has been recognised in profit and loss account (Refer note no.9). Deferred income tax assets and liabilities are recognised for deductible and taxable temporary differences arising between the tax base of assets and liabilities and their carrying amount in financial statements using the tax rates and laws that are enacted or substantively enacted as on the balance sheet date.”

O. Provisions, Contingent Liabilities and Contingent Assets

Provisions involving substantial degree of estimation in measurement are recognized when there is a present obligation as a result of past events and it is probable that there will be an outflow of resources. Contingent Liabilities are not recognised but are disclosed in the notes. Contingent Assets are neither recognized nor disclosed in the financial statements.

Notes to standalone financial statements for the Period ended 31st March 2021

(All amounts in Indian Rupees lacs, unless stated otherwise)

3. Property, plant and equipment

	Freehold land	Buildings	Plant and equipment	Office equipment	Furniture and fixtures	Computer	Vehicles	Total	Capital work-in-progress
Cost									
At 01 April 2019	875.94	1,386.83	1,313.67	1,547.02	68.98	12.26	292.70	5,497.40	189.15
Additions	-	31.49	-	79.84	-	5.20	60.82	177.35	1.19
Disposals/Adjustments	-	-	-	14.15	-	-	80.89	95.04	-
At 31 March 2020	875.94	1,418.32	1,313.67	1,612.71	68.98	17.46	272.63	5,579.71	190.34
Additions	-	190.34	16.28	11.29	5.75	25.72	29.00	278.38	-
Disposals/Adjustments	-	-	83.58	-	-	-	-	83.58	-
Transfer to Buildings	-	-	-	-	-	-	-	-	190.34
At 31st March 2021	875.94	1,608.66	1,246.37	1,624.00	74.73	43.18	301.63	5,774.51	-
Accumulated Depreciation									
At 01 April 2019	-	638.73	1,123.43	1,301.19	46.77	1.11	224.78	3,336.01	-
Depreciation for the year	-	19.37	23.88	47.07	6.25	4.85	11.56	112.98	-
Disposals	-	-	-	-	-	-	75.30	75.30	-
At 31 March 2020	-	658.10	1,147.31	1,348.26	53.02	5.96	161.04	3,373.69	-
Depreciation for the year	-	21.38	23.39	36.37	4.72	7.74	15.00	108.60	-
Disposals	-	-	42.44	-	-	-	-	42.44	-
Transfer to Right of use asset	-	-	-	-	-	-	-	-	-
At 31st March 2021	-	679.48	1,128.26	384.63	57.74	13.70	176.04	3,439.85	-
Net book value									
At 31st March 2021	875.94	929.18	118.11	239.37	16.99	29.48	125.59	2,334.66	-
At 31 March 2020	875.94	760.22	166.36	264.45	15.96	11.50	111.59	2,206.02	190.34

Notes to standalone financial statements for the Period ended 31st March 2021

(All amounts in Indian Rupees lacs, unless stated otherwise)

4. Intangible assets

	Goodwill	Product development cost	Total
Cost			
At 01 April 2019	3.00	206.27	209.27
Additions		28.26	28.26
Disposals		-	-
At 31 March 2020	3.00	234.53	237.53
Additions		-	-
Disposals	-	-	-
At 31 March 2021	3.00	234.53	237.53
Amortisation			
At 01 April 2019			-
Amortisation for the year		-	-
Disposals		-	-
At 31 March 2020	-	-	-
Amortisation for the year		-	-
Disposals	-	-	-
At 31 March 2021	-	-	-
Net book value			
At 31 March 2021	3.00	234.53	237.53
At 31 March 2020	3.00	234.53	237.53

Notes to standalone financial statements for the Period ended 31st March 2021

(All amounts in Indian Rupees lacs, unless stated otherwise)

5. Investments

	As at 31 March 2021		As at 31 March 2020	
	Quantity	Value	Quantity	Value
A. Non-current investments				
Investment in equity of Sun Pharmaceuticals Ltd (1043 fully paid shares)	1,043	0.05	1,043	0.05
Investment in equity of Naari Pharma Private Limited (20439 Equity Shares of Face value of Rs.10 (2.93%))	20,439	1,004.43	20,439	1,004.43
Investment in 10.5 % Perp Bond of Indusind Bank		101.79		101.79
Tata Healthcare Fund		69.57		12.41
ADTHERA Consumers Brands Pvt. Ltd. (Investment in Compulsory Convertible Cumulative Preference Share)	6,667	10.00		-
Artwork		20.00		20.00
Total		1,205.84		1,138.68
Aggregate amount of quoted/unquoted investments		1,205.84		1,138.68
Aggregate amount of impairment in value of investments		-		-

B. Current investments				
	As at 31 March 2021		As at 31 March 2020	
	Quantity	Value	Quantity	Value
Quoted investment in mutual funds <i>(At fair value routed through profit and loss)</i>	225,361	325.07	-	-
Total		325.07		-
Aggregate amount of quoted investments (cost)		325.07		-

Notes to standalone financial statements for the Period ended 31st March 2021
(All amounts in Indian Rupees lacs, unless stated otherwise)

6. Loans

A. Non-current		
	As at 31 March 2021	As at 31 March 2020
Unsecured, considered good		
Security deposits	44.22	51.72
	44.22	51.72

B. Current		
	As at 31 March 2021	As at 31 March 2020
Unsecured, considered good		
Loan to employees	26.77	32.89
	26.77	32.89

7. Other financial assets

A. Non-current (Unsecured, considered good, unless stated otherwise)		
	As at 31 March 2021	As at 31 March 2020
Margin money deposits	28.61	-
	28.61	-

B. Current (Unsecured, considered good, unless stated otherwise)		
	As at 31 March 2021	As at 31 March 2020
Derivative instruments at fair value through profit and loss		
Foreign exchange forward contracts	-	-
At amortised cost		
Other receivables	25.03	36.09
	25.03	36.09

Break up of financial assets carried at amortised cost

	As at 31 March 2021	As at 31 March 2020
Loans (Refer note 6)	70.99	84.61
Trade receivables (Refer note 12)	1,266.40	2,145.34

Cash and cash equivalents (Refer note 13)	5,894.29	3,981.30
Other bank balances (Refer note 14)	128.69	67.21
Other financial assets	53.64	36.09
Total financial assets carried at amortised cost	7,414.01	6,314.55

Break up of financial assets carried at fair value through profit and loss

	As at 31 March 2021	As at 31 March 2020
Other financial assets	-	-
	-	-

8. Non-current tax assets (net)

	As at 31 March 2021	As at 31 March 2020
Advance income-tax	457.76	1,401.47
	457.76	1,401.47

9. Deferred tax assets/ Liabilities (net)

	As at 31 March 2021	As at 31 March 2020
Deferred tax asset relates to the following:		
Provision for employee benefits	25.19	
Total deferred tax asset (A)	25.19	-
Deferred tax liability relates to the following:		
Property, plant and equipment	211.05	309.16
Total deferred tax liabilities (B)	211.05	309.16
Deferred tax Liability recognised (net) (C = A-B)	185.86	309.16

The movement in net deferred tax liability has been recorded through statement of profit and loss.

The Company offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax authority.

The company has changed accounting policy (Refer Note 2N) and has now adopted Balance sheet approach in place of Profit and Loss approach followed earlier for calculation of Deferred Tax Assets/ Deferred Tax Liabilities. Due to the change in the accounting policy the current year tax expenditure has been reduced to the tune of INR 119.31 lacs. As a result, profit after tax has increased by the same amount.

In assessing the realisability of deferred tax assets, management considers whether it is probable, that some portion, or all, of the deferred tax assets will not be realised. The ultimate realisation of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences become deductible. Management considers the projected future taxable income and tax planning strategies in making this assessment. Based on the level of historical taxable income and projections for future taxable incomes over the periods in which the deferred tax assets are deductible, management believes that it is probable that the Company will be able to realise the benefits of those deductible differences in future and vice-versa.

10. Other assets
A. Non-current (Unsecured, considered good, unless stated otherwise)

	As at 31 March 2021	As at 31 March 2020
Unsecured, considered good		
Prepaid expenses	-	12.96
MAT Credit Entitlement	63.91	-
	63.91	12.96

B. Current (Unsecured, considered good, unless stated otherwise)

	As at 31 March 2021	As at 31 March 2020
Advances other than capital advances	805.36	-
Balances with statutory authorities	601.37	418.92
Others	2.28	16.40
	1,409.01	435.32

11. Inventories

	As at 31 March 2021	As at 31 March 2020
Valued at lower of cost and net realisable value		
Raw materials and components	694.24	126.32
Work-in-progress	1,031.29	595.63
Finished goods	1,246.92	2,210.55
	2,972.45	2,932.50

12. Trade receivables

	As at 31 March 2021	As at 31 March 2020
Trade receivables	1,309.88	2,145.34
Receivables from related parties (Refer note 37)	-	-
Less: Provision for Bad Debts	(43.48)	-
	1,266.40	2,145.34

Break-up for security details and more than six months overdue:

	As at 31 March 2021	As at 31 March 2020
Outstanding for a period exceeding six months from the date they are due for payment		
Unsecured, considered Good	-	49.51
Unsecured, considered Doubtful	43.48	-
Provision for doubtful receivables	(43.48)	-
	-	49.51
	-	49.51
Other receivables		
Unsecured, considered good	1,266.40	2,095.83
	1,266.40	2,095.83
Total trade receivables	1,266.40	2,145.34

Neither trade or other receivable are due from directors or other officers of the Company, either severally or jointly with any other person nor any trade or other receivable are due from firms or private companies respectively in which any director is a partner, a director or a member.

Trade receivables are non-interest bearing and are generally on terms of 30 to 180 days.

13. Cash and cash equivalents

	As at 31 March 2021	As at 31 March 2020
Balance with banks:		
- In current accounts*	944.89	673.17
- In Fixed deposit	4,918.26	3,280.38
Cash in hand**	31.14	27.75
	5,894.29	3,981.30

* Bank balance includes debit balance of cash credit account which was shown under short term borrowings in the previous year.

** Cash in hand includes cash held as imprest balances.

14. Other bank balances

	As at 31 March 2021	As at 31 March 2020
Interest accrued on fixed deposits	128.69	67.21
	128.69	67.21

Notes to standalone financial statements for the Period ended 31st March 2021

(All amounts in Indian Rupees lacs, unless stated otherwise)

15. Share capital

a) Authorised share capital

	As at 31 March 2021		As at 31 March 2020	
	No of Shares	Amount in Lacs	No of Shares	Amount in Lacs
Equity Shares of INR 5/- each with voiting rights	30,000,000	1,500	30,000,000	1,500
Equity Shares of INR 5/- each with differential voiting rights	20,000,000	1,000	20,000,000	1,000

b) Terms/rights attached to equity shares

The Company has equity shares with voting rights and differential voting rights having par value of INR 5 per share and having entitlement to vote accordingly. The Company declares and pays dividends in Indian rupees. The dividend, if any, proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

c) Issued subscribed and paid up equity capital

	Number of shares	Amount
Equity shares of INR 5 each issued, subscribed and fully paid		
At 1 April 2019	26,198,000	1,309.90
Issue during the year	-	-
Buy back during the year	-	-
At 31 March 2020	26,198,000	1,309.90
Issue during the year	-	-
Buy back during the year	-	-
At 31 March 2021	26,198,000	1,309.90

d) Details of shareholders holding more than 5% equity shares in the Company

Name of the shareholder	As at 31 March 2021		As at 31 March 2020	
	Number of shares	% holding	Number of shares	% holding
Equity shares of INR 5 each, fully paid				
Body Corporate				
Aresko Progressive Pvt Ltd	17,215,254	65.71	17,215,254	65.71

As per records of the Company, including its register of shareholders/ members and other declarations received from shareholders regarding beneficial interest, the above shareholding represents both legal and beneficial ownerships of shares.

e) Distributions made and proposed

The amount of per share dividend recognized as distribution to equity shareholder for the year ended 31st March 2021 and 31st March 2020 was INR 1.00/- and INR 0.50/- respectively.

16. Other equity

	As at 31 March 2021	As at 31 March 2020
General reserve		
Balance as per the last financial statements	4,180.22	4,180.22
Add: Amount transferred from surplus balance in the statement of profit and loss	-	-
Closing Balance	4,180.22	4,180.22
Securities premium account		
Balance as per the last financial statements	60.00	60.00
Add: Amount transferred from surplus balance in the statement of profit and loss	-	-
Closing Balance	60.00	60.00
Revaluation Reserve		
Balance as per the last financial statements	783.92	783.92
Add: Amount transferred from surplus balance in the statement of profit and loss	-	-
Closing Balance	783.92	783.92
Surplus/ (deficit) in the statement of profit and loss		
Balance as per last financial statements	4,769.35	4,113.27
Profit for the year	1,705.83	787.08
Other comprehensive income	15.16	-
Less: Appropriations		
Equity dividend	262.00	131.00
Earlier years adjustment in DBO and Income tax*	369.47	-
Total appropriations	631.47	131.00
Net surplus in the statement of profit and loss	5,858.87	4,769.35
Total other equity	10,883.01	9,793.49

General Reserve

General reserves are the retained earnings of a company which are kept aside out of company's profits to meet future (known or unknown) obligations. Moreover, this reserve arises from the transfer portion of the net profits pursuant to the earlier provisions of Companies Act 1956. Mandatory transfer to general reserve is not required under the Companies Act 2013.

Surplus/ (deficit) in the statement of profit and loss

Represents the profits generated by the Company that are not distributed to shareholders and are re-invested in the Company.

* Represents INR 220.54 lacs on account of recognition of earlier year defined benefit obligations and INR 148.93 lacs on account of writing off of earlier years Income tax.

17. Borrowings**A. Non-current**

	As at 31 March 2021	As at 31 March 2020
Term loans		
Loans	-	-
	-	-
Total	-	-
Less: Current maturities classified to other financial liabilities (Refer Note 22)	-	-
	-	-

B. Current

	As at 31 March 2021	As at 31 March 2020
Loan from Director & Bank		
Unsecured loans- From directors *	678.79	640.37
	678.79	640.37

* Also refer to explanation to note 13.

18. Lease Liabilities

	Building	Total
Lease liability		
As at 1st April 2019		-
Interest expense		-
Lease payments		-
At 31 March 2020	-	-
Current		
Non-current	-	-
Provisions		
A. Non-current		

	As at 31 March 2021	As at 31 March 2020
Provision for employee benefits		
Provision for gratuity (Refer note 36)	1.80	-
	1.80	-

B. Current

	As at 31 March 2021	As at 31 March 2020
Provision for employee benefits		
Provision for gratuity (Refer note 36)	84.68	-
Provision for leave encashment	-	-
	84.68	-

Notes to standalone financial statements for the Period ended 31st March 2021

(All amounts in Indian Rupees lacs, unless stated otherwise)

20. Government grants

	As at 1 April	Addition/ Recognition	Utilisation	As at 31 March
Financial Year 2019-20				
Investment in property, plant and equipment	-	-	-	-
Loan at below market-rate of interest	-	-	-	-
Export Promotion Capital Goods (EPCG) scheme	-	-	-	-
Duty exemption scheme	-	-	-	-
	-	-	-	-
Non-current	-			-
Current	-			-
Financial Year 2020-21				
Investment in property, plant and equipment	-	-	-	-
Loan at below market-rate of interest	-	-	-	-
Export Promotion Capital Goods (EPCG) scheme	-	-	-	-
Duty exemption scheme	-	-	-	-
	-	-	-	-
Non-current	-			-
Current	-			-

A. Duty exemption scheme - Duty exemption scheme allows import of raw and packing material required for the production of exportable goods. Under this scheme, the Company has to achieve both the quantity and FOB value of exports specified in the license. The export obligation is to be fulfilled within a specified period from the date of issuance of license. Such grants are released to the statement of profit and loss based on the fulfillment of related export obligations.

Notes to standalone financial statements for the Period ended 31st March 2021

(All amounts in Indian Rupees lacs, unless stated otherwise)

21. Trade payables

	As at 31 March 2021	As at 31 March 2020
Trade payables		
- Due to micro and small enterprises*	218.23	275.98
- Others	1,586.76	894.95
	1,804.99	1,170.93

Trade payables are non-interest bearing and normally settled between credit period of 30 to 180 days. Refer Note 41 for the Company's credit risk management process.

Details of dues to micro and small enterprises as defined under the MSMED Act, 2006:

S.no.	Particulars	31 March 2021	31 March 2020
(i)	The principal amount and the interest due thereon remaining unpaid to any supplier as at the end of each accounting year		
	- Principal amount due to micro and small enterprises*	218.23	275.98
	- Interest due on above	-	-
(ii)	The amount of interest paid by the buyer in terms of section 16 of the MSMED Act 2006 along with the amounts of the payment made to the supplier beyond the appointed day during each accounting year	-	-
(iii)	The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act 2006	-	-
(iv)	The amount of interest accrued and remaining unpaid at the end of each accounting year	-	-
(v)	The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under section 23 of the MSMED Act 2006	-	-

* Dues to the micro and small enterprises has been determined to the extent such parties have been identified on the basis of information collected by the management. This has been relied upon the auditors.

Notes to standalone financial statements for the Period ended 31st March 2021

(All amounts in Indian Rupees lacs, unless stated otherwise)

22. Other financial liabilities (Current)

	As at 31 March 2021	As at 31 March 2020
At amortised cost		
Employee related liabilities	420.25	372.71
Others	18.00	18.00
	438.25	390.71

Break up of financial liabilities carried at amortised cost

	As at 31 March 2021	As at 31 March 2020
Borrowings (Refer note 17)	678.79	640.37
Trade payables (Refer note 21)	1,804.99	1,170.93
Other financial liabilities	438.25	390.71
Total financial liabilities carried at amortised cost	2,922.03	2,202.01

23. Current tax liabilities

	As at 31 March 2021	As at 31 March 2020
Provision for income tax	382.15	829.98
	382.15	829.98

24. Other current liabilities

	As at 31 March 2021	As at 31 March 2020
Statutory liabilities	181.06	128.65
Advance from customers	-	-
Other Expense Payable	207.75	165.18
Proposed Dividend	262.00	131.00
	650.81	424.83

Notes to standalone financial statements for the Period ended 31st March 2021

(All amounts in Indian Rupees lacs, unless stated otherwise)

25 Revenue from operations

(A) Revenue from Contract with Customers

Particulars	For the year ended 31 March 2021	For the year ended 31 March 2020
Sale of products	18,787.56	15,856.78
Sale of Service	-	-
Total	18,787.56	15,856.78

25.1 Disaggregated revenue information

Set out below is the disaggregation of the Company's revenue from contracts with customers:

Segment

Particulars	For the year ended 31 March 2021	For the year ended 31 March 2020
Revenue from sale of goods	18,787.56	15,856.78
Revenue from Sale of service	-	-
Total revenue from contracts with customers	18,787.56	15,856.78
India	18,064.29	15,409.15
Outside India	723.27	447.63
Total revenue from contracts with customers	18,787.56	15,856.78

25.2 Contract balances

Particulars	As at 31 March 2021	As at 31 March 2020
Trade receivables	1,266.40	2,145.34
Contract liabilities	-	-

Trade receivables are non interest bearing. Credit period generally falls in the range of 30 to 180 days.

Contract liabilities includes advances received from customers to deliver goods.

25.3 Reconciling the amount of revenue recognised in the statement of profit and loss with the contracted price

Particulars	For the year ended 31 March 2021	For the year ended 31 March 2020
Revenue as per contracted price net of discounts and returns	18,787.56	15,856.78
Revenue from contracts with customers	18,787.56	15,856.78

25.4 Performance obligations**Products**

Obligation of the Company is to sell products as per the specification agreed with the customers, if in case there is any deviation then product supplied will be replaced with new product.

(B) Other operating income

Particulars	For the year ended 31 March 2021	For the year ended 31 March 2020
Scrap sales	7.00	-
Total	7.00	-
Total revenue from operations (A+B)	18,794.56	15,856.78

Notes to standalone financial statements for the Period ended 31st March 2021

(All amounts in Indian Rupees lacs, unless stated otherwise)

26. Other income

	For the year ended 31 March 2021	For the year ended 31 March 2020
Interest income on		
Banks deposits	299.24	216.80
Provisions/liabilities no longer required written back	79.39	-
Fair value gain on financial instruments at fair value through profit or loss	25.05	-
Net gain/ loss on disposal of property, plant and equipment	-	(1.60)
Miscellaneous income	35.65	37.42
	439.33	252.62

27. Cost of raw and packing materials consumed

	For the year ended 31 March 2021	For the year ended 31 March 2020
Inventory at the beginning of the year	126.32	338.09
Add: Purchases	4,431.37	3,466.71
	4,557.69	3,804.80
Less: Inventory at the end of the year	694.24	126.32
Cost of raw and packaging material	3,863.45	3,678.48

* Includes cost of raw material and components consumed on account of contract manufacturing .

28. (Increase)/ decrease in inventories

	For the year ended 31 March 2021	For the year ended 31 March 2020	(Increase)/ decrease
Inventories at the end of the year			
Finished goods	1,031.29	595.63	(435.66)
Work-in-progress	1,246.92	2,210.55	963.63
Scrap	-	-	-
	2,278.21	2,806.18	527.97
Inventories at the beginning of the year			
Finished goods	595.63	482.33	(113.30)
Work-in-progress	2,210.55	2,448.84	238.29
Scrap	-	-	-
	2,806.18	2,931.17	124.99
	527.97	124.99	

Notes to standalone financial statements for the Period ended 31st March 2021

(All amounts in Indian Rupees lacs, unless stated otherwise)

29. Employee benefit expense

	For the year ended 31 March 2021	For the year ended 31 March 2020
Salaries, wages and bonus	5,007.24	4,491.90
Contribution to provident and other funds	279.22	323.12
Gratuity expense (Refer note 36)	97.19	120.39
Staff welfare expenses	14.47	102.01
	5,398.12	5,037.42

30. Depreciation and amortisation expense

	For the year ended 31 March 2021	For the year ended 31 March 2020
Depreciation on property, plant and equipment	108.60	112.98
Amortisation of intangible assets	-	-
	108.60	112.98

31. Finance costs

	For the year ended 31 March 2021	For the year ended 31 March 2020
Interest on borrowings	42.75	38.31
Bank charges	8.60	13.10
	51.35	51.41

32. Other expenses

	For the year ended 31 March 2021	For the year ended 31 March 2020
Consumption of stores and spares	1.98	-
Power and fuel	52.30	75.62
Material handling costs	13.81	6.51
Rent	226.87	206.53
Rates and taxes	103.12	108.19
Insurance	76.18	80.74
Repairs and maintenance		
Buildings	3.45	0.81
Plant and Machinery	0.56	0.06
Others	42.10	43.65
CSR expenditure (Refer note A below)	2.36	7.85
Travelling and conveyance	1,102.68	1,718.68
Communication costs	37.89	42.88
Printing and stationery	28.87	51.59
Legal and professional fees	272.15	137.43
Advertising and sales promotion	1,183.48	1,629.40
Freight and forwarding charges	115.53	116.08
Product registration expenses	6.80	-
Payment to auditor (Refer note B below)	20.72	8.95
Charity and donation	0.00	0.25
Provision for doubtful debts and advances	43.48	-
Miscellaneous expenses	76.65	112.23
	3,410.98	4,347.45

A. Details of CSR expenditure		
	For the year ended 31 March 2021	For the year ended 31 March 2020
a) Gross amount required to be spent by the Company during the year	2.36	7.85
(b) Amount spent during the year ending on 31 March 2021	Yet to be paid in cash	Total
i) Construction/acquisition of any asset	-	-
ii) On purposes other than (i) above	2.36	2.36
(c) Amount spent during the year ending on 31 March 2020	Yet to be paid in cash	Total
i) Construction/acquisition of any asset	-	-
ii) On purposes other than (i) above	-	7.85
B. Payment to auditors		
	For the year ended 31 March 2021	For the year ended 31 March 2020
To auditor		
Audit fee	3.00	3.00
Tax audit fee	1.20	1.20
GST Audit Fees	1.50	1.50
In other capacity	0.40	0.35
Reimbursement of expenses	3.00	3.00
To Cost Auditor	1.75	1.75
	10.85	10.80
33. Income tax expense		
The major components of income tax expense for the years ended 31 March 2021 and 31 March 2020 are:		
(a) Profit or loss section		
	For the year ended 31 March 2021	For the year ended 31 March 2020
Current income tax:		
Current income tax charge net of tax impact on OCI	610.93	157.15
Deferred tax:		
Relating to origination and reversal of temporary differences	(123.30)	(2.75)
Income tax expense reported in the statement of profit or loss	487.63	154.40

(b) Other comprehensive income (OCI section)

	For the year ended 31 March 2021	For the year ended 31 March 2020
Deferred tax related to items recognised in OCI during in the year:		
Net loss/(gain) on remeasurements of defined benefit plans	(6.23)	-
Income tax charged to OCI	(6.23)	-

(c) Reconciliation of tax expenses and the accounting profit multiplied by India's tax rate:

	For the year ended 31 March 2021	For the year ended 31 March 2020
Accounting profit before income tax	2,187.23	941.48
Indian tax rate as applicable to the Company	29.12%	27.82%
Tax at the tax rates as applicable to the Company	636.92	261.92
Adjustment in respect of current income tax of previous year	-	-
MAT credit Utilized	-	(42.95)
Tax effect of amounts which are not deductible (taxable) in calculating taxable income:		
Effect of Income not taxable	(7.29)	(0.01)
Effect of expenditure not allowed	28.99	-
Effect of different tax rate on certain items (depreciation)	3.99	7.16
Other	(51.68)	0.62
Benefit of previously unrecognised tax loss to reduce current tax expense	-	(69.59)
Other Comprehensive Income	(6.23)	
Effect of remeasurement of Deferred Tax Liabilities	(123.30)	(2.75)
At the effective income tax rate of 29.12% (31 March 2020: 27.82%)	481.40	154.40
Tax expense as recognised in statement of profit and loss	481.40	154.40

The tax rate of 29.12% (25% + surcharge @12% and cess @4%) used for the year 2020-21 and 27.82% (25% + surcharge @7% and cess @4%) used for the year 2019-20 is the corporate tax rate applicable on taxable profits under the Income-tax Act, 1961.

34. Earnings per share (EPS)

Basic EPS is calculated by dividing the profit for the year attributable to equity holders by the weighted average number of equity shares outstanding during the year.

For the purpose of calculating diluted EPS, the net profit for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period is adjusted for the effects of all dilutive potential equity shares.

The following reflects the income and share data used in the basic and diluted EPS computations:

	For the year ended 31 March 2021	For the year ended 31 March 2020
Profit attributable to equity holders for basic earnings	1,705.83	787.08
Effect of dilution	-	-
Profit attributable to equity holders for the effect of dilution	1,705.83	787.08
Weighted average number of equity shares for basic EPS	261.98	261.98
Effect of dilution	-	-
Weighted average number of equity shares adjusted for the effect of dilution	261.98	1,309.90
Basic EPS (absolute value in INR)	6.51	3.00
Diluted EPS (absolute value in INR)	6.51	3.00

-There are no extra-ordinary items/ exceptional items to consider for calculating basic and diluted earning per share.
-EPS for continuing operations and total operations are same.

Notes to standalone financial statements for the Period ended 31st March 2021

(All amounts in Indian Rupees lacs, unless stated otherwise)

35. Commitments and contingencies
(a) Leases
Operating lease commitments - Company as lessee

The Company has taken various office premises and warehouses under operating lease agreements. These leases are renewable by mutual consent on mutually agreed terms. The company has not entered into any long term lease rental contracts. The Company has recognised INR 226.87lacs (31 March 2020: INR 206.53 lacs) in respect of such leases.

(b) Capital and other commitments

i. There are no contracts remaining to be executed on capital account and therefore are not provided for.

(c) Contingent liabilities and commitments (to the extent not provided for)

	For the year ended 31 March 2021	For the year ended 31 March 2020
VAT/ Sale tax demands	599.26	605.57

36. Gratuity and other employment benefit plans
a. Disclosures related to defined contribution plan

(Amount)

	For the year ended 31 March 2021	For the year ended 31 March 2020
Contribution to Provident and other funds	279.22	323.12

b. Disclosures related to defined benefit plan

The Company operates a defined benefit gratuity plan. The Gratuity is computed as 15 days salary, for every completed year of service or part thereof in excess of 6 months and is payable on retirement/termination/resignation. The benefit vests on the employee completing 5 years of service. The company has taken a group gratuity scheme from an Insurance Company (LIC). The annual contributions as demanded by the Insurance Company (LIC) has been paid. The Company makes provision of gratuity asset/ liability in the books of accounts on the basis of actuarial valuation as per the projected unit credit method.

The components of the Gratuity plan benefit obligations are shown below:

Present value of defined benefit obligation (Amount)

	For the year ended 31 March 2021	For the year ended 31 March 2020
Balance as at the beginning of the year	920.08	498.95
Service cost	85.45	68.53
Interest cost	52.89	28.52
Benefits paid by LIC	(0.30)	(5.62)
Benefits paid by company	(177.15)	(120.38)
Actuarial loss	(12.01)	450.08
Balance as at the end of the year	868.96	920.08

Fair value of plan assets**(Amount)**

	For the year ended 31 March 2021	For the year ended 31 March 2020
Balance as at the beginning of the year	699.54	645.57
Expected return on plan assets	41.15	37.10
Contributions	32.71	12.08
Benefits paid	(0.30)	(5.62)
Actuarial (loss)/gain	9.38	10.41
Balance as at the end of the year	782.48	699.54

The major categories of plan assets as a percentage of the fair value of total plan assets are as follows:

(Amount)

	For the year ended 31 March 2021	For the year ended 31 March 2020
Investments with Insurance Company (LIC)	100%	100%

The reconciliation of the present value of obligations and the fair value of plan assets to the assets and liabilities is as below:

(Amount)

	For the year ended 31 March 2021	For the year ended 31 March 2020
Fair value of plan assets as at the end of the year	782.48	699.54
Present value of defined benefit obligations as at end of the year	(868.96)	(920.08)
Liability recognised in the Balance Sheet as at the end of the year	(86.48)	(220.54)

The net gratuity cost for the below mentioned years is as follows:

	(Amount)	
	For the year ended 31 March 2020	For the year ended 31 March 2019
Service cost	85.45	68.53
Interest cost	52.89	28.52
Expected return on plan assets	(41.15)	(37.10)
Net actuarial loss	(21.39)	439.67
Net gratuity cost	75.80	499.62

Amount recognised in statement of profit and loss:

	(Amount)	
	For the year ended 31 March 2020	For the year ended 31 March 2019
Service cost	85.45	68.53
Net interest cost	11.74	(8.58)
Amount recognised in statement of profit and loss	97.19	59.95

Amount recognised in other comprehensive income:

	(Amount)	
	For the year ended 31 March 2020	For the year ended 31 March 2019
Actuarial loss on obligations	(12.01)	450.08
Return on plan assets (excluding amounts included in net interest expense)	(9.38)	(10.41)
Amount recognised in other comprehensive income	(21.39)	439.67

The principal assumptions used in determining gratuity benefit obligations for the Company's plans are shown below:

Actuarial assumptions

	For the year ended 31 March 2020	For the year ended 31 March 2019
Discounting rate	5.60%	5.75%
Future salary increase	7.00%	7.00%

The estimates of future salary increases, considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors such as supply and demand factors in the employment market.

The overall expected rate of return on assets is determined based on the market prices prevailing on that date, applicable to the period over which the obligation is to be settled.

The maturity profile of defined benefit obligation (Undiscounted):

	(Amount)
Within the next 12 months (next annual reporting period)	390.67
Between 2 and 5 years	269.94
Between 5 and 10 years	202.80

Notes to standalone financial statements for the Period ended 31st March 2021

(All amounts in Indian Rupees lacs, unless stated otherwise)

37. Related party transactions**Names of related parties and related party relationship**

The names of the related parties of the Company and the nature of relationship is as follows:

S.No.	Nature of relationship	Name of the party
1	Associates	Naari Pharma Pvt Ltd
2	Key management personnel	Mr. Rajpal Singh Kochhar Mrs. Jasbir Kaur Kochhar Mr. Bharat Sinh Mr. Ashok Kumar Pati Mr. Ishpal Singh Ghai Mr. Mammen Mathew Mr. Sanjiv Kumar Dudeja Mr R.K.Kapoor (Late) Ms. Nandita Singh
3	Relatives of KMP	Indepal Singh Kochhar

Terms and conditions of transactions with related parties

The sales to and purchases from related parties are made on terms equivalent to those that prevail in arm's length transactions. Outstanding balances at the year-end are unsecured and interest free and settlement occurs in cash. For the year ended 31 March 2021, the Company has not recorded any impairment of receivables relating to amounts owed by related parties (31 March 2020: Nil). This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.

Disclosure of transactions between the Company and related parties and the status of outstanding balances are as under:

S. No.	Particulars	31 March 2021	31 March 2020
A.	Associates - Naari Pharma Pvt Ltd		
	-Purchases	51.77	102.46
S. No.	Particulars	31 March 2021	31 March 2020
B.	Key management personnel		
1	Mr. Rajpal Singh Kochhar		
	Transactions during the year		
	Compensation during the year		
	Short-term employee benefits	117.71	100.88
2	Mrs. Jasbir Kaur Kochhar		
	Transactions during the year		
	Rent expense paid	30.00	-
	Interest	38.42	42.06
3	Mr. Bharat Sinh		
	Transactions during the year		
	Short-term employee benefits	2.00	2.00
	Professional fees and director sitting fees	0.48	0.58

4	Mr. Ashok Kumar Pati Transactions during the year Professional fees and director sitting fees	0.38	0.23
5	Mr. Ishpal Singh Ghai Transactions during the year Short-term employee benefits Professional fees and director sitting fees	2.00 0.48	2.00 0.58
6	Mr. Mammen Mathew Transactions during the year Professional fees and director sitting fees	0.20	0.10
7	Mr. Sanjiv Kumar Dudeja Transactions during the year Short-term employee benefits	58.94	56.80
8	Mr R.K.Kapoor (Late) Transactions during the year Short-term employee benefits	-	2.90
9	Ms. Nandita Singh Transactions during the year Compensation during the year Short-term employee benefits	- 6.43	- 3.51

C. Relatives of KMP

S. No.	Particulars	31 March 2021	31 March 2020
1	Inderpal Singh Kochhar Transactions during the year Compensation during the year Short-term employee benefits	42.11	42.08
	Balance outstanding at the year end		
	Naari Pharma Pvt. Ltd.	20.35	(8.76)
	Unsecured Laon from Jasbir Kaur Kochhar	678.79	640.37

Notes to standalone financial statements for the Period ended 31st March 2021

(All amounts in Indian Rupees lacs, unless stated otherwise)

38. Segment information

In accordance with Indian Accounting Standard (Ind AS) 108 on Operating segments, company has identified pharmaceutical business as its primary segment and its information has been given in the standalone financial statements of the Company, and therefore no separate disclosure on segment information is given in these financial statements.

39. Significant accounting judgements, estimates and assumptions

The preparation of the Company's financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, accompanying disclosures and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.

Judgements

In the process of applying the Company's accounting policies, management has made the following judgements, which have the most significant effect on the amounts recognised in the financial statements:

In the process of applying the Company's accounting policies, management has made the following judgements,

which have the most significant effect on the amounts recognised in the financial statements:

(a) Determination of functional currency

The determination of functional currency often requires significant judgement where the primary economic environment in which they operate may not be clear. In determining the functional currency, judgement is required to determine the currency that mainly reflects the economic substance of the underlying economic event.

(b) Determining the lease term of contracts with renewal and termination options - the Company as lessee

“The Company determines the lease term as the non-cancellable term of the lease, together with any periods covered by an option to extend the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably certain not to be exercised.

The Company has several lease contracts that include extension and termination options. The Company applies judgement in evaluating whether it is reasonably certain whether or not to exercise the option to renew or terminate the lease. That is, it considers all relevant factors that create an economic incentive for it to exercise either the renewal or termination. After the commencement date, the Company reassesses the lease term if there is a significant event or change in circumstances that is within its control and affects its ability to exercise or not to exercise the option to renew or to terminate.”

(c) Taxes

The Company based on its business plan along with supporting convincing evidence including future projections of profit believes that the used tax credits would be utilised within the stipulated time period as per the Income Tax Act, 1961.

Estimates and assumptions

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. The Company based its assumptions and estimates on parameters available when the financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Company. Such changes are reflected in the assumptions when they occur.

(a) Impairment of non-financial assets

The carrying amounts of the Company’s non-financial assets are reviewed for impairment at each balance sheet date if there is any indication of impairment based on internal and external factors. If any such indication exists, then the asset’s recoverable amount is estimated.

The recoverable amount of an asset or cash-generating

unit (CGU) is the greater of the assets value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU. The fair value less costs of disposal calculation is based on available data from binding sales transactions, conducted at arm’s length, for similar assets or observable market prices less incremental costs for disposing of the asset.

For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (‘CGU’).

Market related information and estimates are used to determine the recoverable amount. Key assumptions on which management has based its determination of recoverable amount include estimated long term growth rates, weighted average cost of capital and estimated operating margins. Cash flow projections take into account past experience and represent management’s best estimate about future developments.

(b) Fair value measurement of financial instruments

When the fair values of financial assets and financial liabilities recorded in the balance sheet cannot be measured based on quoted prices in active markets, their fair value is measured using valuation techniques including the discounted cash flow model. The inputs to these models are taken from observable markets where possible, but where this is not feasible, a degree of judgement is required in establishing fair values. Judgements include considerations of inputs such as liquidity risk, credit risk volatility and discount rates. Changes in assumptions about these factors could affect the reported fair value of financial instruments. See note 42 for further disclosures.

(c) Useful life of property, plant and equipment and intangible assets

The carrying value of property, plant and equipment and intangible assets is arrived at by depreciating the assets over the useful life of assets. The management believes that the useful lives currently used fairly reflect its estimate of the useful lives and residual values. The estimate of useful life is reviewed at the end of each financial year and changes are accounted for prospectively.

(d) Defined benefit plans

The cost of the defined gratuity plan along with their present values are determined using actuarial valuations. An actuarial valuation involves making various assumptions that may differ from the actual developments in the future. These include the determination of the discount rate, future salary increases and mortality rates. Due to the complexities involved in the valuation and its long-term nature, a defined benefit obligation is highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date.

The parameter most subject to change is the discount rate. In determining the appropriate discount rate for plans operated in India, the management considers the interest rates of government bonds in currencies consistent with the currencies of the post-employment benefit obligation. The mortality rate is based on publicly available mortality tables for the specific countries. Those mortality tables tend to change only at interval in response to demographic changes. Future salary increases and gratuity increases are based on expected future inflation rates. Further details about gratuity obligations are given in Note 37.

(e) Taxes

In assessing the realisability of deferred tax assets, management considers whether it is probable, that some portion, or all, of the deferred tax assets will not be realised. The ultimate realisation of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences become deductible. Management considers the projected future taxable income and tax planning strategies in making this assessment. Based on the level of historical taxable income and projections for future taxable incomes over the periods in which the deferred tax assets are deductible, management believes that it is probable that the Company will be able to realise the benefits of those deductible differences in future.

(f) Provisions and contingencies

The assessments undertaken in recognising provisions and contingencies have been made in accordance with the applicable Ind AS. A provision is recognised, if as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Where the effect of time value of money is material, provisions are determined by discounting the expected future cash flows

In the normal course of business, contingent liabilities may arise from litigation and other claims against the Company. There are certain obligations which the management has concluded, based on all available facts and circumstances, are not probable of payment and such obligations are treated as contingent liabilities and disclosed in the notes but are not reflected as liabilities in the financial statements. Refer note 35 (c).

(g) Leases - Estimating the incremental borrowing rate

“The Company cannot readily determine the interest rate implicit in the lease, therefore, it uses its incremental borrowing rate (IBR) to measure lease liabilities. The IBR is the rate of interest that the Group would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment. The IBR therefore reflects what the Company ‘would have to pay’, which requires estimation when no observable

rates are available or when they need to be adjusted to reflect the terms and conditions of the lease. The Company estimates the IBR using observable inputs (such as market interest rates) when available. Currently this is not applicable as the company does not have any long term lease agreements”

Notes to standalone financial statements for the Period ended 31st March 2021

(All amounts in Indian Rupees lacs, unless stated otherwise)

41. Financial risk management objectives and policies

The Company’s principal financial liabilities comprise borrowings, trade and other payables. The main purpose of these financial liabilities is to finance the Company’s operations. The Company’s principal financial assets include trade and other receivables and cash and cash equivalents that derive directly from its operations.

The Company is exposed primarily to market risk, credit risk and liquidity risk. The Company’s risk management assessment and policies are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls, and to monitor such risks and compliance with the same. Risk assessment and management policies are reviewed regularly to reflect changes in market conditions and the Company’s activities. The Board of Directors and the Audit Committee is responsible for overseeing the Company’s risk assessment and management policies.

(a) Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Such changes in the values of financial instruments may result from changes in the foreign currency exchange rates, interest rates, prices, liquidity and other market changes. The Company’s exposure to market risk is primarily on account of foreign currency exchange rate risk and interest rate risk.

(i) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company’s exposure to the risk of changes in market interest rates because it borrows funds at both fixed and floating interest rates. The Company manages its interest rate risk by having a balanced portfolio of fixed and variable rate loans and borrowings.

As the Company has no significant interest bearing assets, the income and operating cash flows are substantially independent of changes in market interest rates.

(i) Price risk

The Company is mainly exposed to the price risk due to its investment in mutual funds. The price risk arises due to uncertainties about the future market values of these investments. The Company has diversified its investments to manage the price risk.

(b) Credit risk

Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. Credit risk encompasses of both, the direct risk of default and the risk of deterioration of creditworthiness as well as concentration of risks. Credit risk is controlled by analysing credit limits and creditworthiness of customers on a continuous basis to whom the credit has been granted after obtaining necessary approvals of credit. Financial instruments that are subject to concentrations of credit risk principally consist of trade receivables, investments, derivative financial instruments, cash and cash equivalents, loans and other financial assets. None of the financial instruments of the Company result in material concentration of credit risk.

Trade receivables and other financial assets:

The Company's exposure to credit risk is influenced mainly by the individual characteristics of each customer. However, the management also evaluates the factors that may influence the credit risk of its customer base, including the default risk and country

in which the customers operate. The management has established a credit policy under which each new customer is analysed individually for creditworthiness before the Company's standard payment and delivery terms and conditions are offered. The Company's review includes external ratings, if available, financial statements, credit agency information, industry information and in some cases bank references.

An impairment analysis is performed at each reporting date on an individual basis for major clients. In addition, a large number of minor receivables are grouped into homogenous groups and assessed for impairment collectively. The Company assesses at each reporting date whether a financial asset or a group of financial assets is impaired. The maximum exposure to credit risk at the reporting date is the carrying value of trade and other receivables.

Concentration of credit risk with respect to trade receivables is limited, since the majority of the Company's revenue is generated from group companies. All trade receivables other than from group companies are reviewed and assessed for default on a regular basis. The Company's receivables turnover is quick and historically, there was no significant default on account of trade and other receivables.

Notes to standalone financial statements for the Period ended 31st March 2021

(All amounts in Indian Rupees lacs, unless stated otherwise)

43. Reconciliation of liabilities arising from financing activities

	31 March 2020	Cash flows	Reclassification	Non -cash changes		31 March 2021
				Foreign exchange movement	Fair value changes	
Long-term borrowings	-	-	-	-	-	-
Short-term-term borrowings	640.37	38.42	-	-	-	678.79
Total liabilities from financing activities	640.37	38.42	-	-	-	678.79

44. COVID-19 has been declared a global pandemic by the World Health Organization with adverse impact on economy and business especially after nationwide lockdown. However, this has not significantly impacted the operations of the Company as the operations of the Company are of essential goods and sale of these goods were exempt from the purview of the lock down.

Further, the Company has assessed the possible effects that may result from COVID-19 on the carrying amounts of financial assets, advances, property plant and equipment, inventory etc. as well as liabilities accrued. Based on such assessment, the management expects the carrying amount of these assets will be recovered and there is no significant impact on liabilities accrued. Further, as on the signing of these financial statements, based on the above facts, the management is confident that there will not be any negative impact of Covid-19 in its business and operations.

45. Events after the reporting period

There are no significant events that occurred after the reporting period.

46. Long- term contracts

The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

47. Balance Confirmations

- i. Interest Income has been accounted for based upon the certificate issued by the banker.
- ii. The balances in parties accounts as at 31st March 2021 are subject to confirmation/ reconciliation in some of the cases. Adjustments , if any, upon due recociliation thereof is proposed to be accounted for in future. The management ,however, is of the view that the impact of adjustment entries ,if any, would not be significant.

48. Inventories

Inventories as at 31st March 2021 were taken and certified by the management as third party verification could not be done due to corona pandemic.

49. Previous years figures have ben rearranged/ regrouped wherever necessary to make them comparable with that of current period figures.

50. Approval of financial statements

The standalone financial statements were approved by the board of directors and approved for issue on 30 June 2021.

As per our report of even date

For H L Bansal and CO.

Chartered Accountants

FRN. NO. 008563N

Hira Lal Bansal

Partner

M.No. 086990

Place: New Delhi

Date: 30 June 2021

For and on behalf of the Board of Directors

For Jagsonpal Pharmaceuticals Limited

R.P.S Kochhar

DIN 00059492

Chairman & Managing Director

S.K. Dudeja

Chief Financial Officer

Nandita Singh

Company Secretary